Author: "Rokx, C." - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Rokx, C."' showing total 158 results

Start Over Author "Rokx, C."

158 results on '"Rokx, C."'

1. Unmasking Individual and Institutional HIV Stigma in Hospitals: Perspectives of Dutch Healthcare Providers

Author: Jordans, C. C. E., Vliegenthart-Jongbloed, K. J., van Bruggen, A. W., van Holten, N., van Beek, J. E. A., Vriesde, M., van der Sluis, D., Verbon, A., Roukens, A. H. E., Stutterheim, S. E., and Rokx, C.
Published: 2024
Full Text: View/download PDF

2. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection

Author: Abela, I., Aebi-Popp, K., Anagnostopoulos, A., Battegay, M., Bernasconi, E., Braun, D.L., Bucher, H.C., Calmy, A., Cavassini, M., Ciuffi, A., Dollenmaier, G., Egger, M., Elzi, L., Fehr, J., Fellay, J., Furrer, H., Fux, C.A., Günthard, H.F., Hachfeld, A., Haerry, D., Hasse, B., Hirsch, H.H., Hoffmann, M., Hösli, I., Huber, M., Jackson-Perry, D., Kahlert, C.R., Kaiser, L., Keiser, O., Klimkait, T., Kouyos, R.D., Kovari, H., Kusejko, K., Labhardt, N., Leuzinger, K., de Tejada B, Martinez, Marzolini, C., Metzner, K.J., Müller, N., Nemeth, J., Nicca, D., Notter, J., Paioni, P., Pantaleo, G., Perreau, M., Rauch, A., Salazar-Vizcaya, L., Schmid, P., Speck, R., Stöckle, M., Tarr, P., Trkola, A., Wandeler, G., Weisser, M., Yerly, S., van der Valk, M., Geerlings, S.E., Goorhuis, A., Harris, V.C., Hovius, J.W., Lempkes, B., Nellen, F.J.B., van der Poll, T., Prins, J.M., Spoorenberg, V., van Vugt, M., Wiersinga, W.J., Wit, F.W.M.N., Bruins, C., van Eden, J., Hylkema-van den Bout, I.J., van Hes, A.M.H., Pijnappel, F.J.J., Smalhout, S.Y., Weijsenfeld, A.M., Back, N.K.T., Berkhout, B., Cornelissen, M.T.E., van Houdt, R., Jonges, M., Jurriaans, S., Schinkel, C.J., Wolthers, K.C., Zaaijer, H.L., Peters, E.J.G., van Agtmael, M.A., Autar, R.S., Bomers, M., Sigaloff, K.C.E., Heitmuller, M., Laan, L.M., van den Berge, M., Stegeman, A., Baas, S., Hage de Looff, L., van Arkel, A., Stohr, J., Wintermans, B., Pronk, M.J.H., Ammerlaan, H.S.M., de Munnik, E.S., Deiman, B., Jansz, A.R., Scharnhorst, V., Tjhie, J., Wegdam, M.C.A., van Eeden, A., Hoornenborg, E., Nellen, J., Alers, W., Elsenburg, L.J.M., Nobel, H., van Kasteren, M.E.E., Berrevoets, M.A.H., Brouwer, A.E., de Kruijf-van de Wiel, B.A.F.M., Adams, A., Rijkevoorsel, M. Pawels-van, Buiting, A.G.M., Murck, J.L., Rokx, C., Anas, A.A., Bax, H.I., van Gorp, E.C.M., de Mendonça Melo, M., van Nood, E., Nouwen, J.L., Rijnders, B.J.A., Schurink, C.A.M., Slobbe, L., de Vries-Sluijs, T.E.M.S., Bassant, N., van Beek, J.E.A., Vriesde, M., van Zonneveld, L.M., de Groot, J., van Kampen, J.J.A., Koopmans, M.P.G., Rahamat-Langendoen, J.C., Branger, J., Douma, R.A., Cents-Bosma, A.S., Duijf-van de Ven, C.J.H.M., Schippers, E.F., van Nieuwkoop, C., Geilings, J., van Winden, S., van der Hut, G., van Burgel, N.D., Leyten, E.M.S., Gelinck, L.B.S., Mollema, F., Wildenbeest, G.S., Nguyen, T., Groeneveld, P.H.P., Bouwhuis, J.W., Lammers, A.J.J., van Hulzen, A.G.W., Kraan, S., Kruiper, M.S.M., van der Bliek, G.L., Bor, P.C.J., Debast, S.B., Wagenvoort, G.H.J., Roukens, A.H.E., de Boer, M.G.J., Jolink, H., Lambregts, M.M.C., Scheper, H., Dorama, W., van Holten, N., Claas, E.C.J., Wessels, E., Hollander, J.G. den, El Moussaoui, R., Pogany, K., Brouwer, C.J., Heida-Peters, D., Mulder, E., Smit, J.V., Struik-Kalkman, D., van Niekerk, T., Pontesilli, O., van Tienen, C., Lowe, S.H., Lashof, A.M.L. Oude, Posthouwer, D., van Wolfswinkel, M.E., Ackens, R.P., Burgers, K., Elasri, M., Schippers, J., Havenith, T.R.A., van Loo, M., van Vonderen, M.G.A., Kampschreur, L.M., van Broekhuizen, M.C., S, Faber, Al Moujahid, A., Kootstra, G.J., Delsing, C.E., van der Burg-van de Plas, M., Scheiberlich, L., Kortmann, W., van Twillert, G., Renckens, R., Wagenaar, J., Ruiter-Pronk, D., van Truijen-Oud, F.A., Stuart, J.W.T. Cohen, Hoogewerf, M., Rozemeijer, W., Sinnige, J.C., Brinkman, K., van den Berk, G.E.L., Lettinga, K.D., de Regt, M., Schouten, W.E.M., Stalenhoef, J.E., Veenstra, J., Vrouenraets, S.M.E., Blaauw, H., Geerders, G.F., Kleene, M.J., Knapen, M., Kok, M., van der Meché, I.B., Toonen, A.J.M., Wijnands, S., Wttewaal, E., Kwa, D., van de Laar, T.J.W., van Crevel, R., van Aerde, K., Dofferhoff, A.S.M., Henriet, S.S.V., Hofstede, H.J.M. ter, Hoogerwerf, J., Richel, O., Albers, M., Grintjes-Huisman, K.J.T., de Haan, M., Marneef, M., McCall, M., Burger, D., Gisolf, E.H., Claassen, M., Hassing, R.J., Beest, G. ter, van Bentum, P.H.M., Gelling, M., Neijland, Y., Swanink, C.M.A., Velderman, M. Klein, van Lelyveld, S.F.L., Soetekouw, R., van der Prijt, L.M.M., van der Swaluw, J., Kalpoe, J.S., Wagemakers, A., Vahidnia, A., Lauw, F.N., Verhagen, D.W.M., van Wijk, M., Bierman, W.F.W., Bakker, M., van Bentum, R.A., van den Boomgaard, M.A., Kleinnijenhuis, J., Kloeze, E., Middel, A., Postma, D.F., Schenk, H.M., Stienstra, Y., Wouthuyzen-Bakker, M., Boonstra, A., de Jonge, H., Maerman, M.M.M., de Weerd, D.A., van Eije, K.J., Knoester, M., van Leer-Buter, C.C., Niesters, H.G.M., T.Mudrikova, Barth, R.E., Bruns, A.H.W., Ellerbroek, P.M., Hensgens, M.P.M., Oosterheert, J.J., Schadd, E.M., Verbon, A., van Welzen, B.J., Berends, H., Santen, B.M.G. Griffioen-van, de Kroon, I., Lunel, F.M. Verduyn, Wensing, A.M.J., Zaheri, S., Boyd, A.C., Bezemer, D.O., van Sighem, A.I., Smit, C., Hillebregt, M.M.J., Woudstra, T.J., Rutkens, T., Bergsma, D., Brétin, N.M., Lelivelt, K.J., van de Sande, L., van der Vliet, K.M. Visser.S.T., Paling, F., de Groot-Berndsen, L.G.M., van den Akker, M., Alexander, R., Bakker, Y., El Berkaoui, A., Bezemer-Goedhart, M., Djoechro, E.A., Groters, M., Koster, L.E., Lodewijk, C.R.E., Lucas, E.G.A., Munjishvili, L., Peeck, B.M., Ree, C.M.J., Regtop, R., van Rijk, A.F., Ruijs-Tiggelman, Y.M.C., Schnörr, P.P., Schoorl, M.J.C., Tuijn, E.M., Veenenberg, D.P., Witte, E.C.M., Bretin, N.M., Karpov, I., Losso, M., Lundgren, J., Rockstroh, J., Aho, I., Rasmussen, L.D., Novak, P., Pradier, C., Chkhartishvili, N., Matulionyte, R., Oprea, C., Kowalska, J.D., Begovac, J., Miró, J.M., Guaraldi, G., Paredes, R., Peters, L., Larsen, J.F., Neesgaard, B., Jaschinski, N., Fursa, O., Raben, D., Kristensen, D., Fischer, A.H., Jensen, S.K., Elsing, T.W., Gardizi, M., Mocroft, A., Phillips, A., Reekie, J., Cozzi-Lepri, A., Pelchen-Matthews, A., Roen, A., Tusch, E.S., Bannister, W., Bellecave, P., Blanco, P., Bonnet, F., Bouchet, S., Breilh, D., Cazanave, C., Desjardin, S., Gaborieau, V., Gimbert, A., Hessamfar, M., Lacaze-Buzy, L., Lacoste, D., Lafon, M.E., Lazaro, E., Leleux, O., Le Marec, F., Le Moal, G., Malvy, D., Marchand, L., Mercié, P., Neau, D., Pellegrin, I., Perrier, A., Petrov-Sanchez, V., Vareil, M.O., Wittkop, L., Bernard, N., Chaussade, D. Bronnimann H., Dondia, D., Duffau, P., Faure, I., Morlat, P., Mériglier, E., Paccalin, F., Riebero, E., Rivoisy, C., Vandenhende, M.A., Barthod, L., Dauchy, F.A., Desclaux, A., Ducours, M., Dutronc, H., Duvignaud, A., Leitao, J., Lescure, M., Nguyen, D., Pistone, T., Puges, M., Wirth, G., Courtault, C., Camou, F., Greib, C., Pellegrin, J.L., Rivière, E., Viallard, J.F., Imbert, Y., Thierry-Mieg, M., Rispal, P., Caubet, O., Ferrand, H., Tchamgoué, S., Farbos, S., Wille, H., Andre, K., Caunegre, L., Gerard, Y., Osorio-Perez, F., Chossat, I., Iles, G., Labasse-Depis, M., Lacassin, F., Barret, A., Castan, B., Koffi, J., Rouanes, N., Saunier, A., Zabbe, J.B., Dumondin, G., Beraud, G., Catroux, M., Garcia, M., Giraud, V., Martellosio, J.P., Roblot, F., Pasdeloup, T., Riché, A., Grosset, M., Males, S., Bell, C. Ngo, Carpentier, C., Bellecave, Virology P., Tumiotto, C., Miremeont-Salamé, G., Arma, D., Arnou, G., Blaizeau, M.J., Camps, P., Decoin, M., Delveaux, S., Diarra, F., Gabrea, L., Lawson-Ayayi, S., Lenaud, E., Plainchamps, D., Pougetoux, A., Uwamaliya, B., Zara, K., Conte, V., Gapillout, M., Surial, Bernard, Ramírez Mena, Adrià, Roumet, Marie, Limacher, Andreas, Smit, Colette, Leleux, Olivier, Mocroft, Amanda, van der Valk, Marc, Bonnet, Fabrice, Peters, Lars, Rockstroh, Jürgen K., Günthard, Huldrych F., Berzigotti, Annalisa, Rauch, Andri, and Wandeler, Gilles
Published: 2023
Full Text: View/download PDF

3. HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study

Author: van der Valk, M., Geerlings, S.E., Goorhuis, A., Hovius, J.W., Lempkes, B., Nellen, F.J.B., van der Poll, T., Prins, J.M., van Vugt, M., Wiersinga, W.J., Wit, F.W.M.N., van Duinen, M., van Eden, J., Hazenberg, A., van Hes, A.M.H., Pijnappel, F.J.J., Smalhout, S.Y., Weijsenfeld, A.M., Jurriaans, S., Back, N.K.T., Zaaijer, H.L., Berkhout, B., Cornelissen, M.T.E., Schinkel, C.J., Wolthers, K.C., Peters, E.J.G., van Agtmael, M.A., Autar, R.S., Bomers, M., Sigaloff, K.C.E., Heitmuller, M., Laan, L.M., Ang, C.W., van Houdt, R., Jonges, M., van den Berge, M., Stegeman, A., Baas, S., Hage de Looff, L., Buiting, A., Reuwer, A., Veenemans, J., Wintermans, B., Pronk, M.J.H., Ammerlaan, H.S.M., van den Bersselaar, D.N.J., de Munnik, E.S., Deiman, B., Jansz, A.R., Scharnhorst, V., Tjhie, J., Wegdam, M.C.A., van Eeden, A., Nellen, J., Brokking, W., Elsenburg, L.J.M., Nobel, H., van Kasteren, M.E.E., Berrevoets, M.A.H., Brouwer, A.E., Adams, A., van Erve, R., de Kruijf-van de Wiel, B.A.F.M., Keelan-Phaf, S., van de Ven, B., Buiting, A.G.M., Murck, J.L., de Vries-Sluijs, T.E.M.S., Bax, H.I., van Gorp, E.C.M., de Jong-Peltenburg, N.C., de Mendonça Melo, M., van Nood, E., Nouwen, J.L., Rijnders, B.J.A., Rokx, C., Schurink, C.A.M., Slobbe, L., Verbon, A., Bassant, N., van Beek, J.E.A., Vriesde, M., van Zonneveld, L.M., de Groot, J., Boucher, C.A.B., Koopmans, M.P.G., van Kampen, J.J.A., Branger, J., Douma, R.A., Cents-Bosma, A.S., Duijf-van de Ven, C.J.H.M., Schippers, E.F., van Nieuwkoop, C., van IJperen, J.M., Geilings, J., van Burgel, N.D., Leyten, E.M.S., van der Hut, G., Gelinck, L.B.S., Mollema, F., Davids-Veldhuis, S., Tearno, C., Wildenbeest, G.S., Heikens, E., Groeneveld, P.H.P., Bouwhuis, J.W., Lammers, A.J.J., Kraan, S., van Hulzen, A.G.W., Kruiper, M.S.M., van der Bliek, G.L., Bor, P.C.J., Debast, S.B., Wagenvoort, G.H.J., Kroon, F.P., de Boer, M.G.J., Jolink, H., Lambregts, M.M.C., Roukens, A.H.E., Scheper, H., Dorama, W., van Holten, N., Claas, E.C.J., Wessels, E., den Hollander, J.G., Brouwer, C.J., Smit, J.V., Struik-Kalkman, D., van Niekerk, T., El Moussaoui, R., Pogany, K., Pontesilli, O., Lowe, S.H., Oude Lashof, A.M.L., Posthouwer, D., van Wolfswinkel, M.E., Ackens, R.P., Burgers, K., Schippers, J., Weijenberg-Maes, B., van Loo, I.H.M., Havenith, T.R.A., van Vonderen, M.G.A., Kampschreur, L.M., Faber, S., Steeman-Bouma, R., Al Moujahid, A., Kootstra, G.J., Delsing, C.E., van der Burg-van de Plas, M., Scheiberlich, L., Kortmann, W., van Twillert, G., Renckens, R., Ruiter-Pronk, D., van Truijen-Oud, F.A., Cohen Stuart, J.W.T., Jansen, E.R., Hoogewerf, M., Rozemeijer, W., van der Reijden, W.A., Sinnige, J.C., Brinkman, K., van den Berk, G.E.L., Blok, W.L., Lettinga, K.D., de Regt, M., Schouten, W.E.M., Stalenhoef, J.E., Veenstra, J., Vrouenraets, S.M.E., Blaauw, H., Geerders, G.F., Kleene, M.J., Kok, M., Knapen, M., van der Meché, I.B., Mulder-Seeleman, E., Toonen, A.J.M., Wijnands, S., Wttewaal, E., Kwa, D., van Crevel, R., Dofferhoff, A.S.M., ter Hofstede, H.J.M., Hoogerwerf, J., Keuter, M., Richel, O., Albers, M., Grintjes-Huisman, K.J.T., de Haan, M., Marneef, M., Strik-Albers, R., Rahamat-Langendoen, J., Stelma, F.F., Burger, D., Gisolf, E.H., Hassing, R.J., Claassen, M., ter Beest, G., van Bentum, P.H.M., Langebeek, N., Tiemessen, R., Swanink, C.M.A., van Lelyveld, S.F.L., Soetekouw, R., van der Prijt, L.M.M., van der Swaluw, J., Bermon, N., Jansen, R., Herpers, B.L., Veenendaal, D., Verhagen, D.W.M., Lauw, F.N., van Broekhuizen, M.C., van Wijk, M., Bierman, W.F.W., Bakker, M., Kleinnijenhuis, J., Kloeze, E., Middel, A., Postma, D.F., Stienstra, Y., Wouthuyzen-Bakker, M., Boonstra, A., de Groot-de Jonge, H., van der Meulen, P.A., de Weerd, D.A., Niesters, H.G.M., van Leer-Buter, C.C., Knoester, M., Hoepelman, A.I.M., Arends, J.E., Barth, R.E., Bruns, A.H.W., Ellerbroek, P.M., Mudrikova, T., Oosterheert, J.J., Schadd, E.M., van Welzen, B.J., Aarsman, K., Griffioen-van Santen, B.M.G., de Kroon, I., van Berkel, M., van Rooijen, C.S.A.M., Schuurman, R., Verduyn-Lunel, F., Wensing, A.M.J., Reiss, P., Zaheri, S., Boyd, A.C., Bezemer, D.O., van Sighem, A.I., Smit, C., Hillebregt, M., de Jong, A., Woudstra, T., Bergsma, D., Meijering, R., van de Sande, L., Rutkens, T., van der Vliet, S., de Groot, L., van den Akker, M., Bakker, Y., El Berkaoui, A., Bezemer, M., Brétin, N., Djoechro, E., Groters, M., Kruijne, E., Lelivelt, K.J., Lodewijk, C., Lucas, E., Munjishvili, L., Paling, F., Peeck, B., Ree, C., Regtop, R., Ruijs, Y., Schoorl, M., Schnörr, P., Scheigrond, A., Tuijn, E., Veenenberg, L., Visser, K.M., Witte, E.C., Smit, Colette, Boyd, Anders, Rijnders, Bart J A, van de Laar, Thijs J W, Leyten, Eliane M, Bierman, Wouter F, Brinkman, Kees, Claassen, Mark A A, den Hollander, Jan, Boerekamps, Anne, Newsum, Astrid M, Schinkel, Janke, Prins, Maria, Arends, Joop E, Op de Coul, Eline L M, van der Valk, Marc, and Reiss, Peter
Published: 2021
Full Text: View/download PDF

4. Real-world effectiveness and tolerability of switching to doravirine-based antiretroviral therapy in people with HIV: a nationwide, matched, prospective cohort study

Author: Oomen, Patrick G A, Wit, Ferdinand W N M, Brinkman, Kees, Vrouenraets, Saskia M E, Mudrikova, Tania, van Welzen, Berend J, van der Valk, Marc, van Agtmael, M.A., Bomers, M., Geerlings, S.E., Goorhuis, A., Harris, V.C., Hovius, J.W., Lemkes, B., Nellen, F.J.B., Peters, E.J.G., van der Poll, T., Prins, J.M., Sigaloff, K.C.E., Spoorenberg, V., van Vugt, M., Wiersinga, W.J., Bruins, C., van Eden, J., Hylkema-van den Bout, I.J., Laan, L.M., Pijnappel, F.J.J., Smalhout, S.Y., Spelbrink, M.E., Weijsenfeld, A.M., Back, N.K.T., Cornelissen, M.T.E., van Houdt, R., Jonges, M., Jurriaans, S., Schinkel, C.J., Welkers, M.R.A., Wolthers, K.C., van den Berge, M., Stegeman, A., Baas, S., Hage de Looff, L., van Arkel, A., Stohr, J., Wintermans, B., Pronk, M.J.H., Ammerlaan, H.S.M., de Bree, C., de Munnik, E.S., Phaf, S., Deiman, B., Jansz, A.R., Scharnhorst, V., Tjhie, J., Wegdam, M.C.A., Nellen, J., van Eeden, A., Hoornenborg, E., de Stoppelaar, S., Alers, W., Elsenburg, L.J.M., Nobel, H., Schinkel, C.J., van Kasteren, M.E.E., Berrevoets, M.A.H., Brouwer, A.E., de Kruijf-van de Wiel, B.A.F.M., Adams, A., Pawels-van Rijkevoorsel, M., Murck, J.L., Rokx, C., Anas, A.A., Bax, H.I., van Gorp, E.C.M., de Mendonça Melo, M., van Nood, E., Nouwen, J.L., Rijnders, B.J.A., Schurink, C.A.M., Slobbe, L., de Vries-Sluijs, T.E.M.S., Bassant, N., van Beek, J.E.A., Vriesde, M., van Zonneveld, L.M., de Groot, J., van Kampen, J.J.A., Koopmans, M.P.G., Rahamat-Langendoen, J.C., Branger, J., Douma, R.A., Cents-Bosma, A.S., Mulder, M.A., Schippers, E.F., van Nieuwkoop, C., Geilings, J., van de Ven, E., van der Hut, G., van Burgel, N.D., Leyten, E.M.S., Gelinck, L.B.S., Mollema, F., Langbein, M., Wildenbeest, G.S., Nguyen, T., Groeneveld, P.H.P., Bouwhuis, J.W., Lammers, A.J.J., van Hulzen, A.G.W., Kraan, S., Kruiper, M.S.M., Debast, S.B., Wagenvoort, G.H.J., Roukens, A.H.E., de Boer, M.G.J., Jolink, H., Lambregts, M.M.C., Scheper, H., van Holten, N., van der Sluis, D., Claas, E.C.J., Wessels, E., den Hollander, J.G., El Moussaoui, R., Pogany, K., Brouwer, C.J., Heida-Peters, D., Mulder, E., Smit, J.V., Struik-Kalkman, D., van Niekerk, T., Pontesilli, O., van Tienen, C., Lowe, S.H., Oude Lashof, A.M.L., Posthouwer, D., Stoop, A., van Wolfswinkel, M.E., Ackens, R.P., Elasri, M., Houben-Pintaric, K., Schippers, J., Havenith, T.R.A., van Loo, M., van Vonderen, M.G.A., Kampschreur, L.M., Timmer, C., van Broekhuizen, M.C., Faber, S., Al Moujahid, A., Kootstra, G.J., Delsing, C.E., van der Burg-van de Plas, M., Scheiberlich, L., Kortmann, W., van Twillert, G., Renckens, R., Wagenaar, J., Ruiter-Pronk, D., Stander, B., Cohen Stuart, J.W.T., Hoogewerf, M., Rozemeijer, W., Sinnige, J.C., Brinkman, K., van den Berk, G.E.L., Lettinga, K.D., de Regt, M., Schouten, W.E.M., Stalenhoef, J.E., Blaauw, H., Geerders, G.F., Kleene, M.J., Knapen, M., Kok, M., van der Meché, I.B., Toonen, A.J.M., Wijnands, S., Wttewaal, E., Kwa, D., van de Laar, T.J.W., van Crevel, R., van Aerde, K., Dofferhoff, A.S.M., Henriet, S.S.V., ter Hofstede, H.J.M., Hoogerwerf, J., Richel, O., Albers, M., Grintjes-Huisman, K.J.T., de Haan, M., Marneef, M., McCall, M., Rahamat-Langendoen, J., Ruizendaal, E., Burger, D., Gisolf, E.H., Claassen, M., Hassing, R.J., ter Beest, G., van Bentum, P.H.M., Neijland, Y., Valette, M., Swanink, C.M.A., Klein Velderman, M., van Lelyveld, S.F.L., Soetekouw, R., van der Prijt, L.M.M., van der Swaluw, J., Kalpoe, J.S., Wagemakers, A., Vahidnia, A., Lauw, F.N., Verhagen, D.W.M., van Wijk, M., Bierman, W.F.W., Bakker, M., van Bentum, R.A., van den Boomgaard, M.A., Kleinnijenhuis, J., Kloeze, E., Middel, A., Postma, D.F., Schenk, H.M., Stienstra, Y., Wouthuyzen-Bakker, M., Boonstra, A., Maerman, M.M.M., de Weerd, D.A., van Eije, K.J., Knoester, M., van Leer-Buter, C.C., Niesters, H.G.M., Barth, R.E., Bruns, A.H.W., Ellerbroek, P.M., Hensgens, M.P.M., Oosterheert, J.J., Schadd, E.M., Verbon, A., Griffioen-van Santen, B.M.G., de Kroon, I., Schuurman, R., Verduyn Lunel, F.M., Wensing, A.M.J., van der Valk, M., Zaheri, S., Boyd, A.C., Bezemer, D.O., Jongen, V.W., van Sighem, A.I., Smit, C., Wit, F.W.M.N., Hillebregt, M.M.J., Woudstra, T.J., Rutkens, T., Bergsma, D., Brétin, N.M., Koster, L.E., Lelivelt, K.J., van de Sande, L., Schoorl, M.J.C., Visser, K.M., van der Vliet, S.T., Paling, F., van den Akker, M., Akpomukai, O.M., Alexander, R., Bakker, Y.M., Bastos Sales, L., El Berkaoui, A., Bezemer-Goedhart, M., Djoechro, E.A., Grolleman, J.M., El Hammoud, I., Khouw, M.R., Lodewijk, C.R.E., Lucas, E.G.A., van Meerveld-Derks, S., Mulder, H.W., Munjishvili, L., Ree, C.M.J., Regtop, R., van Rijk, A.F., Ruijs-Tiggelman, Y.M.C., Schnörr, P.P., van Veen, R., van Vliet-Klein Gunnewiek, W.H.G., and Witte, E.C.M.
Abstract: Currently, real-world data on doravirine are scarce. In a national prospective cohort, we assessed the effectiveness and tolerability of switching to doravirine-based antiretroviral therapy (ART) in people with HIV.
Published: 2024
Full Text: View/download PDF

5. Non-AIDS Events in Individuals With Spontaneous Control of HIV-1

Author: Groenendijk, Albert L., Vos, Wilhelm A. J. W., Dos Santos, J.C., Rokx, C., Ven, A.J.A.M. van der, and Verbon, A.
Subjects: Acquired Immunodeficiency Syndrome, All institutes and research themes of the Radboud University Medical Center, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Infectious Diseases, SDG 3 - Good Health and Well-being, Cardiovascular Diseases, HIV Seropositivity, lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], HIV-1, Humans, HIV Infections, Pharmacology (medical)
Abstract: BACKGROUND: Despite antiretroviral therapy (ART), people living with HIV (PLHIV) are at increased risk for non-AIDS-defining events (nADEs), including cardiovascular events, non-AIDS malignances, hepatic disease, and bacterial pneumonia. SETTING: This systematic review seeks to answer the question: are PLHIV who spontaneously control HIV-1 subject to an increased risk of various nADEs relative to noncontrolling PLHIV on ART and people without HIV? METHODS: Databases were searched on June 9, 2021 with a search syntax focused on the elements "HIV," "spontaneous control," and "clinical outcomes": Embase.com (includes Embase and Medline), Medline Ovid (includes PubMed), Cochrane library, Web of Science, and Google Scholar. Included were studies reporting non-AIDS events in spontaneous controllers. Excluded were case reports, conference papers, editorials, and reviews. RESULTS: Of 1134 identified records, 34 were assessed for full-text and 12 studies were included in the qualitative synthesis: 5 cohorts, 2 cross-sectional prevalence studies, 4 cross-sectional imaging studies, and one case series. Four of 5 cohort studies showed that spontaneous controllers have a similar risk to develop nADEs compared with PLHIV on suppressive ART, specifically cardiovascular events, non-AIDS malignancies, hepatic disease, and bacterial pneumonia. Cross-sectional imaging studies showed a higher presence of subclinical cardiovascular disease in spontaneous controllers, than in people without HIV. CONCLUSION: Individuals with spontaneous control of HIV-1 do not seem to be at a greater risk to develop different nADEs compared with PLHIV on suppressive ART. More data are needed, because the present conclusions are based on a limited number of studies that show large heterogeneity among them.
Published: 2022

6. Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA)

Author: Prins, H.A.B., primary, Zino, L., additional, Svensson, E.M., additional, Verbon, A., additional, de Bree, G.J., additional, Prins, J.M., additional, Reiss, P., additional, Burger, D.M., additional, Rokx, C., additional, and Colbers, A., additional
Published: 2023
Full Text: View/download PDF

7. Evaluation of HIV-1 reservoir size and broadly neutralizing antibody (bNAb) susceptibility in individuals who initiated ART during acute and chronic infection

Author: Moldt, B., Gunthard, H., Workowski, K., Little, S., Eron, J., Overton, E., Lehmann, C., Rokx, C., Kozal, M., Gandhi, R., Liu, H., Makadzange, T., Collins, S., Geleziunas, R., and Callebaut, C.
Subjects: Antiviral agents -- Patient outcomes, AIDS (Disease) -- Research, AIDS research, HIV infection -- Development and progression -- Care and treatment, Health
Abstract: Background: The persistence of the viral reservoir is the main barrier to curing HIV. Initiation of ART during primary HIV infection can limit the size and diversity of the viral [...]
Published: 2021
Full Text: View/download PDF

8. Outpatient convalescent plasma therapy for high-risk patients with early COVID-19. A randomized placebo-controlled trial

Author: Gharbharan, A., Jordans, C., Zwaginga, L., Papageorgiou, G., Geloven, N. van, Wijngaarden, P. van, Hollander, J. den, Karim, F., Leeuwen-Segarceanu, E. van, Soetekouw, R., Lammers, J., Postma, D., Kampschreur, L., Groeneveld, G., Swaneveld, F., Schoot, C.E. van der, Gotz, H., Haagmans, B., Koopmans, M., Bogers, S., Geurtsvankessel, C., Zwaginga, J.J., Rokx, C., Rijnders, B., CoV-Early study grp, Clinical Haematology, Internal Medicine, Medical Microbiology & Infectious Diseases, Epidemiology, Public Health, and Virology
Subjects: Microbiology (medical), Infectious Diseases, Convalescent plasma, SDG 3 - Good Health and Well-being, Outpatients, COVID-19, General Medicine, Therapy, Antibodies
Abstract: Objectives: The potential benefit of convalescent plasma (CP) therapy for coronavirus disease 2019 (COVID-19) is highest when administered early after symptom onset. Our objective was to determine the effectiveness of CP therapy in improving the disease course of COVID-19 among high-risk outpatients. Methods: A multicentre, double-blind randomized trial was conducted comparing 300 mL of CP with non-CP. Patients were >= 50 years, were symptomatic for 50 years was 80%. Patients had a median age of 60 years, symptoms for 5 days, and 207 of 416 patients received CP therapy. During the 28 day follow-up, 28 patients were hospitalized and two died. The OR for an improved disease severity score with CP was 0.86 (95% credible interval, 0.59-1.22). The OR was 0.58 (95% CI, 0.33-1.02) for patients with
Published: 2022

9. Lupus anticoagulant associates with thrombosis in patients with COVID-19 admitted to intensive care units

Author: Noordermeer, Tessa, Schutgens, Roger E. G., Visser, Chantal, Rademaker, Emma, de Maat, Moniek P. M., Jansen, A. J. Gerard, Limper, Maarten, Cremer, Olaf L., Kruip, Marieke J. H. A., Endeman, Henrik, Maas, Coen, de Laat, Bas, Urbanus, Rolf T., van de Beek, D., Brouwer, M. C., de Bruin, S., Coppens, M., van Es, N., van Haaps, T. F., Juffermans, N. P., Muller, M. C. A., Vlaar, A. P. J., Hertogh, C. M. P. M., Heunks, L. M. A., Hugtenburg, J. G., van Kooten, J., Nossent, E. J., Smulders, Y., Tuinman, P. R., Noordegraaf, A. Vonk, Grootenboers, M. J. J. H., van Guldener, C., Kant, M., Lansbergen, A., Faber, J., Hajer, G., Stemerdink, A., van den Akker, J., Bierings, R., Endeman, H., Goeijenbier, M., Hunfeld, N. G. M., van Gorp, E. C. M., Gommers, D. A. M. P. J., Koopmans, M. P. G., Kruip, M. J. H. A., Kuiken, T., Langerak, T., Leebeek, Lauw, M. N., de Maat, M. P. M., Noack, D., Paats, M. S., Raadsen, M. P., Rockx, B., Rokx, C., Schurink, C. A. M., Tong-Minh, K., van den Toorn, L., den Uil, C. A., Visser, C., Boutkourt, F., Roest, T., Douma, R. A., de Haan, L. R., ten Wolde, M., Bemelmans, R. H. H., Festen, B., Stads, S., de Jager, C. P. C., Simons, K. S., Antoni, M. L., Bos, M. H., Burggraaf, J. L. I., Cannegieter, S. C., Eikenboom, H. C. J., den Exter, P. L., Geelhoed, J. J. M., Huisman, M. V., de Jonge, E., Kaptein, F. H. J., Klok, F. A., Kroft, L. J. M., Lijfering, W. M., Nab, L., Ninaber, M. K., Putter, H., Ramai, S. R. S., da Rocha Rondon, A. M., Roukens, A. H. E., Stals, M. A. M., Versteeg, H. H., Vliegen, H. W., van Vlijmen, B. J. M., van de Berg, T., Bruggemann, R., van Bussel, B. C. T., ten Cate, H., ten Cate-Hoek, A., Hackeng, T. M., Henskens, ir. Y., Hulshof, A., Mulder, M., Olie, R. H., Schurgers, L., Spaetgens, B., Spronk, H., Spruit, M. A., Winckers, K., Nieuwenhuizen, L., Franken, B., Schrover, I. M., de Waal, E. G. M., Beishuizen, A., Cornet, A., Krabbe, J., Kramers, K., Leentjens, J., de Mast, Q., Middeldorp, S., Brouwer, R. E., Ellerbroek, J. L. J., Tijmensen, J., Hovens, M. M. C., Oostdijk, E. A. N., Westerhof, B. D., Faber, L. M., van den Biggelaar, M., Meijers, J. C. M., Voorberg, J., Kevenaar, M. E., Soei, Y. L., Wils, E. J., Croles, F. N., de Laat, B., Kamphuisen, P. W., Vink, R., Lisman, T., Meijer, K., van Tichelaar, Y. I. G., Cremer, O. L., Geersing, G., Kaasjager, H. A. H., Kusadasi, N., Huisman, A., Maas, C., Nijkeuter, M., Schutgens, R. E. G., Creveldkliniek, Van, Urbanus, R. T., Westerink, J., Faber, H. J., Koster, S. C. E., van Montfort, P., van Twist, D. J. L., RS: Carim - B01 Blood proteins & engineering, Biochemie, Hematology, Intensive Care, Neurology, ANS - Neuroinfection & -inflammation, Intensive Care Medicine, ACS - Pulmonary hypertension & thrombosis, AII - Inflammatory diseases, Vascular Medicine, ACS - Amsterdam Cardiovascular Sciences, Graduate School, ACS - Microcirculation, Medical Microbiology and Infection Prevention, ARD - Amsterdam Reproduction and Development, Experimental Vascular Medicine, Landsteiner Laboratory, ACS - Atherosclerosis & ischemic syndromes, Elderly care medicine, APH - Aging & Later Life, Clinical pharmacology and pharmacy, APH - Health Behaviors & Chronic Diseases, Pulmonary medicine, Internal medicine, ACS - Diabetes & metabolism, Intensive care medicine, General practice, and Amsterdam Gastroenterology Endocrinology Metabolism
Subjects: lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], lupus anticoagulant, risk factor, critically ill, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], COVID-19, Hematology, thrombosis, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]
Abstract: Contains fulltext : 286889.pdf (Publisher’s version ) (Open Access) BACKGROUND: Thrombosis is a frequent and severe complication in patients with coronavirus disease 2019 (COVID-19) admitted to the intensive care unit (ICU). Lupus anticoagulant (LA) is a strong acquired risk factor for thrombosis in various diseases and is frequently observed in patients with COVID-19. Whether LA is associated with thrombosis in patients with severe COVID-19 is currently unclear. OBJECTIVE: To investigate if LA is associated with thrombosis in critically ill patients with COVID-19. PATIENTS/METHODS: The presence of LA and other antiphospholipid antibodies was assessed in patients with COVID-19 admitted to the ICU. LA was determined with dilute Russell's viper venom time (dRVVT) and LA-sensitive activated partial thromboplastin time (aPTT) reagents. RESULTS: Of 169 patients with COVID-19, 116 (69%) tested positive for at least one antiphospholipid antibody upon admission to the ICU. Forty (24%) patients tested positive for LA; of whom 29 (17%) tested positive with a dRVVT, 19 (11%) tested positive with an LA-sensitive aPTT, and 8 (5%) tested positive on both tests. Fifty-eight (34%) patients developed thrombosis after ICU admission. The odds ratio (OR) for thrombosis in patients with LA based on a dRVVT was 2.5 (95% confidence interval [CI], 1.1-5.7), which increased to 4.5 (95% CI, 1.4-14.3) in patients at or below the median age in this study (64 years). LA positivity based on a dRVVT or LA-sensitive aPTT was only associated with thrombosis in patients aged less than 65 years (OR, 3.8; 95% CI, 1.3-11.4) and disappeared after adjustment for C-reactive protein. CONCLUSION: Lupus anticoagulant on admission is strongly associated with thrombosis in critically ill patients with COVID-19, especially in patients aged less than 65 years.
Published: 2022

10. The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy

Author: Prins, H.A.B., primary, Crespo, R., additional, Lungu, C., additional, Rao, S., additional, Li, L., additional, Overmars, R.J., additional, Papageorgiou, G., additional, Mueller, Y.M., additional, Hossain, T., additional, Kan, T.W., additional, Rijnders, B.J.A., additional, Bax, H.I., additional, van Gorp, E.C.M., additional, Nouwen, J.L., additional, de Vries-Sluijs, T.E.M.S., additional, Schurink, C.A.M., additional, de Mendonça Melo, M., additional, van Nood, E., additional, Colbers, A., additional, Burger, D., additional, Palstra, R-J., additional, van Kampen, J.J.A., additional, van de Vijver, D.A.M.C., additional, Mesplède, T., additional, Katsikis, P.D., additional, Gruters, R.A., additional, Koch, B.C.P., additional, Verbon, A., additional, Mahmoudi, T., additional, and Rokx, C., additional
Published: 2022
Full Text: View/download PDF

11. A highly virulent variant of HIV-1 circulating in the Netherlands

Author: Wymant, Chris, Bezemer, Daniela, Blanquart, François, Ferretti, Luca, Gall, Astrid, Hall, Matthew, Golubchik, Tanya, Bakker, Margreet, Ong, Swee Hoe, Zhao, Lele, Bonsall, David, de Cesare, Mariateresa, MacIntyre-Cockett, George, Abeler-Dörner, Lucie, Albert, Jan, Bannert, Norbert, Fellay, Jacques, Grabowski, M Kate, Gunsenheimer-Bartmeyer, Barbara, Günthard, Huldrych F, Kivelä, Pia, Kouyos, Roger D, Laeyendecker, Oliver, Meyer, Laurence, Porter, Kholoud, Ristola, Matti, van Sighem, Ard, Berkhout, Ben, Kellam, Paul, Cornelissen, Marion, Reiss, Peter, Fraser, Christophe, Aubert, V, Battegay, M, Bernasconi, E, Böni, J, Braun, D L, Bucher, H C, Burton-Jeangros, C, Calmy, A, Cavassini, M, Dollenmaier, G, Egger, M, Elzi, L, Fehr, J, Fellay, J, Furrer, H, Fux, C A, Gorgievski, M, Günthard, H, Haerry, D, Hasse, B, Hirsch, H H, Hoffmann, M, Hösli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kouyos, R, Kovari, H, Ledergerber, B, Martinetti, G, de Tejada, B Martinez, Marzolini, C, Metzner, K, Müller, N, Nadal, D, Nicca, D, Pantaleo, G, Rauch, A, Regenass, S, Rudin, C, Schöni-Affolter, F, Schmid, P, Speck, R, Stöckle, M, Tarr, P, Trkola, A, Vernazza, P, Weber, R, Yerly, S, van der Valk, M, Geerlings, S E, Goorhuis, A, Hovius, J W, Lempkes, B, Nellen, F J B, van der Poll, T, Prins, J M, Reiss, P, van Vugt, M, Wiersinga, W J, Wit, F W M N, van Duinen, M, van Eden, J, Hazenberg, A, van Hes, A M H, Pijnappel, F J J, Smalhout, S Y, Weijsenfeld, A M, Jurriaans, S, Back, N K T, Zaaijer, H L, Berkhout, B, Cornelissen, M T E, Schinkel, C J, Wolthers, K C, Peters, E J G, van Agtmael, M A, Autar, R S, Bomers, M, Sigaloff, K C E, Heitmuller, M, Laan, L M, Ang, C W, van Houdt, R, Jonges, M, Kuijpers, T W, Pajkrt, D, Scherpbier, H J, de Boer, C, van der Plas, A, van den Berge, M, Stegeman, A, Baas, S, Hage de Looff, L, Buiting, A, Reuwer, A, Veenemans, J, Wintermans, B, Pronk, M J H, Ammerlaan, H S M, van den Bersselaar, D N J, de Munnik, E S, Deiman, B, Jansz, A R, Scharnhorst, V, Tjhie, J, Wegdam, M C A, van Eeden, A, Nellen, J, Brokking, W, Elsenburg, L J M, Nobel, H, van Kasteren, M E E, Berrevoets, M A H, Brouwer, A E, Adams, A, van Erve, R, de Kruijf-van de Wiel, B A F M, Keelan-Phaf, S, van der Ven, B, Buiting, A G M, Murck, J L, de Vries-Sluijs, T E M S, Bax, H I, van Gorp, E C M, de Jong-Peltenburg, N C, de Mendonç A Melo, M, van Nood, E, Nouwen, J L, Rijnders, B J A, Rokx, C, Schurink, C A M, Slobbe, L, Verbon, A, Bassant, N, van Beek, J E A, Vriesde, M, van Zonneveld, L M, de Groot, J, Boucher, C A B, Koopmans, M P G, van Kampen, J J A, Fraaij, P L A, van Rossum, A M C, Vermont, C L, van der Knaap, L C, Visser, E, Branger, J, Douma, R A, Cents-Bosma, A S, Duijf-van de Ven, C J H M, Schippers, E F, van Nieuwkoop, C, van Ijperen, J M, Geilings, J, van der Hut, G, van Burgel, N D, Leyten, E M S, Gelinck, L B S, Mollema, F, Davids-Veldhuis, S, Tearno, C, Wildenbeest, G S, Heikens, E, Groeneveld, P H P, Bouwhuis, J W, Lammers, A J J, Kraan, S, van Hulzen, A G W, Kruiper, M S M, van der Bliek, G L, Bor, P C J, Debast, S B, Wagenvoort, G H J, Kroon, F P, de Boer, M G J, Jolink, H, Lambregts, M M C, Roukens, A H E, Scheper, H, Dorama, W, van Holten, N, Claas, E C J, Wessels, E, den Hollander, J G, El Moussaoui, R, Pogany, K, Smit, J V, Struik-Kalkman, D, van Niekerk, T, Pontesilli, O, Lowe, S H, Oude Lashof, A M L, Posthouwer, D, van Wolfswinkel, M E, Ackens, R P, Burgers, K, Schippers, J, Weijenberg-Maes, B, van Loo, I H M, Havenith, T R A, van Vonderen, M G A, Kampschreur, L M, Faber, S, Steeman-Bouma, R, Al Moujahid, A, Kootstra, G J, Delsing, C E, van der Burg-van de Plas, M, Scheiberlich, L, Kortmann, W, van Twillert, G, Renckens, R, Ruiter-Pronk, D, van Truijen-Oud, F A, Cohen Stuart, J W T, Jansen, E R, Hoogewerf, M, Rozemeijer, W, van der Reijden, W A, Sinnige, J C, Brinkman, K, van den Berk, G E L, Blok, W L, Lettinga, K D, de Regt, M, Schouten, W E M, Stalenhoef, J E, Veenstra, J, Vrouenraets, S M E, Blaauw, H, Geerders, G F, Kleene, M J, Kok, M, Knapen, M, van der Meché, I B, Mulder-Seeleman, E, Toonen, A J M, Wijnands, S, Wttewaal, E, Kwa, D, van Crevel, R, van Aerde, K, Dofferhoff, A S M, Henriet, S S V, Ter Hofstede, H J M, Hoogerwerf, J, Keuter, M, Richel, O, Albers, M, Grintjes-Huisman, K J T, de Haan, M, Marneef, M, Strik-Albers, R, Rahamat-Langendoen, J, Stelma, F F, Burger, D, Gisolf, E H, Hassing, R J, Claassen, M, Ter Beest, G, van Bentum, P H M, Langebeek, N, Tiemessen, R, Swanink, C M A, van Lelyveld, S F L, Soetekouw, R, van der Prijt, L M M, van der Swaluw, J, Bermon, N, Jansen, R, Herpers, B L, Veenendaal, D, Verhagen, D W M, Lauw, F N, van Broekhuizen, M C, van Wijk, M, Bierman, W F W, Bakker, M, Kleinnijenhuis, J, Kloeze, E, Middel, A, Postma, D F, Schölvinck, E H, Stienstra, Y, Verhage, A R, Wouthuyzen-Bakker, M, Boonstra, A, de Groot-de Jonge, H, van der Meulen, P A, de Weerd, D A, Niesters, H G M, van Leer-Buter, C C, Knoester, M, Hoepelman, A I M, Arends, J E, Barth, R E, Bruns, A H W, Ellerbroek, P M, Mudrikova, T, Oosterheert, J J, Schadd, E M, van Welzen, B J, Aarsman, K, Griffioen-van Santen, B M G, de Kroon, I, van Berkel, M, van Rooijen, C S A M, Schuurman, R, Verduyn-Lunel, F, Wensing, A M J, Bont, L J, Geelen, S P M, Loeffen, Y G T, Wolfs, T F W, Nauta, N, Rooijakkers, E O W, Holtsema, H, Voigt, R, van de Wetering, D, Alberto, A, van der Meer, I, Rosingh, A, Halaby, T, Zaheri, S, Boyd, A C, Bezemer, D O, van Sighem, A I, Smit, C, Hillebregt, M, de Jong, A, Woudstra, T, Bergsma, D, Meijering, R, van de Sande, L, Rutkens, T, van der Vliet, S, de Groot, L, van den Akker, M, Bakker, Y, El Berkaoui, A, Bezemer, M, Brétin, N, Djoechro, E, Groters, M, Kruijne, E, Lelivelt, K J, Lodewijk, C, Lucas, E, Munjishvili, L, Paling, F, Peeck, B, Ree, C, Regtop, R, Ruijs, Y, Schoorl, M, Schnörr, P, Scheigrond, A, Tuijn, E, Veenenberg, L, Visser, K M, Witte, E C, Van Frankenhuijsen, Maartje, Allegre, Thierry, Makhloufi, Djamila, Livrozet, Jean-Michel, Chiarello, Pierre, Godinot, Mathieu, Brunel-Dalmas, Florence, Gibert, Sylvie, Trepo, Christian, Peyramond, Dominique, Miailhes, Patrick, Koffi, Joseph, Thoirain, Valérie, Brochier, Corinne, Baudry, Thomas, Pailhes, Sylvie, Lafeuillade, Alain, Philip, Gisèle, Hittinger, Gilles, Assi, Assi, Lambry, Véronique, Rosenthal, Eric, Naqvi, Alissa, Dunais, Brigitte, Cua, Eric, Pradier, Christian, Durant, Jacques, Joulie, Aline, Quinsat, Denis, Tempesta, Serge, Ravaux, Isabelle, Martin, Isabelle Poizot, Faucher, Olivia, Cloarec, Nicolas, Champagne, Hélène, Pichancourt, Gilles, Morlat, Philippe, Pistone, Thierry, Bonnet, Fabrice, Mercie, Patrick, Faure, Isabelle, Hessamfar, Mojgan, Malvy, Denis, Lacoste, Denis, Pertusa, Marie-Carmen, Vandenhende, Marie-Anne, Bernard, Noëlle, Paccalin, François, Martell, Cédric, Roger-Schmelz, Julien, Receveur, Marie-Catherine, Duffau, Pierre, Dondia, Denis, Ribeiro, Emmanuel, Caltado, Sabrina, Neau, Didier, Dupont, Michel, Dutronc, Hervé, Dauchy, Frédéric, Cazanave, Charles, Vareil, Marc-Olivier, Wirth, Gaétane, Le Puil, Séverine, Pellegrin, Jean-Luc, Raymond, Isabelle, Viallard, Jean-François, Chaigne de Lalande, Severin, Garipuy, Daniel, Delobel, Pierre, Obadia, Martine, Cuzin, Lise, Alvarez, Muriel, Biezunski, Noemie, Porte, Lydie, Massip, Patrice, Debard, Alexa, Balsarin, Florence, Lagarrigue, Myriam, Prevoteau du Clary, François, Aquilina, Christian, Reynes, Jacques, Baillat, Vincent, Merle, Corinne, Lemoing, Vincent, Atoui, Nadine, Makinson, Alain, Jacquet, Jean Marc, Psomas, Christina, Tramoni, Christine, Aumaitre, Hugues, Saada, Mathieu, Medus, Marie, Malet, Martine, Eden, Aurélia, Neuville, Ségolène, Ferreyra, Milagros, Sotto, Albert, Barbuat, Claudine, Rouanet, Isabelle, Leureillard, Didier, Mauboussin, Jean-Marc, Lechiche, Catherine, Donsesco, Régine, Cabie, André, Abel, Sylvie, Pierre-Francois, Sandrine, Batala, Anne-Sophie, Cerland, Christophe, Rangom, Camille, Theresine, Nadine, Hoen, Bruno, Lamaury, Isabelle, Fabre, Isabelle, Schepers, Kinda, Curlier, Elodie, Ouissa, Rachida, Gaud, Catherine, Ricaud, Carole, Rodet, Roland, Wartel, Guillaume, Sautron, Carmele, Beck-Wirth, Geneviève, Michel, Catherine, Beck, Charles, Halna, Jean-Michel, Kowalczyk, Jakub, Benomar, Meryem, Drobacheff-Thiebaut, Christine, Chirouze, Catherine, Faucher, Jean-François, Parcelier, François, Foltzer, Adeline, Haffner-Mauvais, Cécile, Hustache Mathieu, Mathieu, Proust, Aurélie, Piroth, Lionel, Chavanet, Pascal, Duong, Michel, Buisson, Marielle, Waldner, Anne, Mahy, Sophie, Gohier, Sandrine, Croisier, Delphine, May, Thierry, Delestan, Mikael, Andre, Marie, Zadeh, Mahsa Mohseni, Martinot, Martin, Rosolen, Béatrice, Pachart, Anne, Martha, Benoît, Jeunet, Noëlle, Rey, David, Cheneau, Christine, Partisani, Maria, Priester, Michèle, Bernard-Henry, Claudine, Batard, Marie-Laure, Fischer, Patricia, Berger, Jean-Luc, Kmiec, Isabelle, Robineau, Olivier, Huleux, Thomas, Ajana, Faïza, Alcaraz, Isabelle, Allienne, Christophe, Baclet, Véronique, Meybeck, Agnès, Valette, Michel, Viget, Nathalie, Aissi, Emmanuelle, Biekre, Raphael, Cornavin, Pauline, Merrien, Dominique, Seghezzi, Jean-Christophe, Machado, Moise, Diab, Georges, Raffi, François, Bonnet, Bénédicte, Allavena, Clotilde, Grossi, Olivier, Reliquet, Véronique, Billaud, Eric, Brunet, Cecile, Bouchez, Sabelline, Morineau-Le Houssine, Pascale, Sauser, Fabienne, Boutoille, David, Besnier, Michel, Hue, Hervé, Hall, Nolwenn, Brosseau, Delphine, Souala, Faouzi, Michelet, Christian, Tattevin, Pierre, Arvieux, Cédric, Revest, Matthieu, Leroy, Helene, Chapplain, Jean-Marc, Dupont, Matthieu, Fily, Fabien, Patra-Delo, Solène, Lefeuvre, Céline, Bernard, Louis, Bastides, Frédéric, Nau, Pascale, Verdon, Renaud, de la Blanchardiere, Arnaud, Martin, Anne, Feret, Philippe, Geffray, Loïk, Daniel, Corinne, Rohan, Jennifer, Fialaire, Pascale, Chennebault, Jean Marie, Rabier, Valérie, Abgueguen, Pierre, Rehaiem, Sami, Luycx, Odile, Niault, Mathilde, Moreau, Philippe, Poinsignon, Yves, Goussef, Marie, Mouton-Rioux, Virginie, Houlbert, Dominique, Alvarez-Huve, Sandrine, Barbe, Frédérique, Haret, Sophie, Perre, Philippe, Leantez-Nainville, Sophie, Esnault, Jean-Luc, Guimard, Thomas, Suaud, Isabelle, Girard, Jean-Jacques, Simonet, Véronique, Debab, Yasmine, Schmit, Jean-Luc, Jacomet, Christine, Weinberck, Pierre, Genet, Claire, Pinet, Pauline, Ducroix, Sophie, Durox, Hélène, Denes, Éric, Abraham, Bruno, Gourdon, Florence, Antoniotti, Odile, Molina, Jean-Michel, Ferret, Samuel, Lascoux-Combe, Caroline, Lafaurie, Matthieu, Colin de Verdiere, Nathalie, Ponscarme, Diane, De Castro, Nathalie, Aslan, Alexandre, Rozenbaum, Willy, Pintado, Claire, Clavel, François, Taulera, Olivier, Gatey, Caroline, Munier, Anne-Lise, Gazaigne, Sandrine, Penot, Pauline, Conort, Guillaume, Lerolle, Nathalie, Leplatois, Anne, Balausine, Stéphanie, Delgado, Jeannine, Timsit, Julie, Tabet, Magda, Gerard, Laurence, Girard, Pierre-Marie, Picard, Odile, Tredup, Jürgen, Bollens, Diane, Valin, Nadia, Campa, Pauline, Bottero, Julie, Lefebvre, Benedicte, Tourneur, Muriel, Fonquernie, Laurent, Wemmert, Charlotte, Lagneau, Jean-Luc, Yazdanpanah, Yazdan, Phung, Bao, Pinto, Adriana, Vallois, Dorothée, Cabras, Ornella, Louni, Françoise, Pialoux, Gilles, Lyavanc, Thomas, Berrebi, Valérie, Chas, Julie, Lenagat, Sophie, Rami, Agathe, Diemer, Myriam, Parrinello, Maguy, Depond, Audrey, Salmon, Dominique, Guillevin, Loïc, Tahi, Tassadit, Belarbi, Linda, Loulergue, Pierre, Zak Dit Zbar, Olivier, Launay, Odile, Silbermann, Benjamin, Leport, Catherine, Alagna, Laura, Pietri, Marie-Pierre, Simon, Anne, Bonmarchand, Manuela, Amirat, Naouel, Pichon, François, Kirstetter, Myriam, Katlama, Christine, Valantin, Marc Antoine, Tubiana, Roland, Caby, Fabienne, Schneider, Luminita, Ktorza, Nadine, Calin, Ruxandra, Merlet, Audrey, Ben Abdallah, Saadia, Weiss, Laurence, Buisson, Martin, Batisse, Dominique, Karmochine, Marina, Pavie, Juliette, Minozzi, Catherine, Jayle, Didier, Castel, Philippe, Derouineau, Jean, Kousignan, Pascale, Eliazevitch, Murielle, Pierre, Isabelle, Collias, Lio, Viard, Jean-Paul, Gilquin, Jacques, Sobel, Alain, Slama, Laurence, Ghosn, Jade, Hadacek, Blanka, Thu-Huyn, Nugyen, Nait-Ighil, Lella, Cros, Agnes, Maignan, Aline, Duvivier, Claudine, Consigny, Paul Henri, Lanternier, Fanny, Shoai-Tehrani, Michka, Touam, Fatima, Jerbi, Saadia, Bodard, Loïc, Jung, Corinne, Goujard, Cécile, Quertainmont, Yann, Duracinsky, Martin, Segeral, Olivier, Blanc, Arnaud, Peretti, Delphine, Cheret, Antoine, Chantalat, Christelle, Dulucq, Marie Josée, Levy, Yves, Lelievre, Jean Daniel, Lascaux, Anne Sophie, Dumont, Cécile, Boue, François, Chambrin, Véronique, Abgrall, Sophie, Kansau, Imad, Raho-Moussa, Mariem, De Truchis, Pierre, Dinh, Aurélien, Davido, Benjamin, Marigot, Dhiba, Berthe, Huguette, Devidas, Alain, Chevojon, Pierre, Chabrol, Amélie, Agher, Nouara, Lemercier, Yvon, Chaix, Fabrice, Turpault, Isabelle, Bouchaud, Olivier, Honore, Patricia, Rouveix, Elisabeth, Reimann, Evelyne, Belan, Alix Greder, Godin Collet, Claire, Souak, Safia, Mortier, Emmanuel, Bloch, Martine, Simonpoli, Anne-Marie, Manceron, Véronique, Cahitte, Isabelle, Hiraux, Emmanuel, Lafon, Erik, Cordonnier, François, Zeng, Ai-Feng, Zucman, David, Majerholc, Catherine, Bornarel, Dominique, Uludag, Agnès, Gellen-Dautremer, Justine, Lefort, Agnès, Bazin, Christine, Daneluzzi, Vincent, Gerbe, Juliette, Jeantils, Vincent, Coupard, Mélissa, Patey, Olivier, Bantsimba, Jonas, Delllion, Sophie, Paz, Pauline Caraux, Cazenave, Benoit, Richier, Laurent, Garrait, Valérie, Delacroix, Isabelle, Elharrar, Brigitte, Vittecoq, Daniel, Bolliot, Claudine, Lepretre, Annie, Genet, Philippe, Masse, Virginie, Perrone, Véronique, Boussard, Jean-Luc, Chardon, Patricia, Froguel, Eric, Simon, Philippe, Tassi, Sylvie, Avettand Fenoel, Véronique, Barin, Francis, Bourgeois, Christine, Cardon, Fanny, Chaix, Marie-Laure, Delfraissy, Jean François, Essat, Asma, Fischer, Hugues, Lecuroux, Camille, Petrov-Sanchez, Ventzislava, Rouzioux, Christine, Saez-Cirion, Asier, Seng, Rémonie, Kuldanek, Kristin, Mullaney, Scott, Young, Carmel, Zucchetti, Antonella, Bevan, Margaret-Ann, McKernan, Sinead, Wandolo, Emily, Richardson, Celia, Youssef, Elaney, Green, Pippa, Faulkner, Sue, Faville, Rebecca, Herman, Sandra, Care, Christine, Blackman, Helen, Bellenger, Katharine, Fairbrother, Keith, Phillips, Andrew, Babiker, Abdel, Delpech, Valerie, Fidler, S, Clarke, Mindy, Fox, Julie, Gilson, R, Goldberg, David, Hawkins, David, Johnson, Anne, Johnson, Margaret, McLean, Ken, Nastouli, Eleni, Post, Frank, Kennedy, N, Pritchard, J, Andrady, U, Rajda, N, Donnelly, C, McKernan, S, Drake, S, Gilleran, G, White, D, Ross, J, Harding, J, Faville, R, Sweeney, J, Flegg, P, Toomer, S, Wilding, H, Woodward, R, Dean, G, Richardson, C, Perry, N, Gompels, M, Jennings, L, Bansaal, D, Browing, M, Connolly, L, Stanley, B, Estreich, S, Magdy, A, O'Mahony, C, Fraser, P, Jebakumar, S P R, David, L, Mette, R, Summerfield, H, Evans, M, White, C, Robertson, R, Lean, C, Morris, S, Winter, A, Faulkner, S, Goorney, B, Howard, L, Fairley, I, Stemp, C, Short, L, Gomez, M, Young, F, Roberts, M, Green, S, Sivakumar, K, Minton, J, Siminoni, A, Calderwood, J, Greenhough, D, DeSouza, C, Muthern, Lisa, Orkin, C, Murphy, S, Truvedi, M, McLean, K, Hawkins, D, Higgs, C, Moyes, A, Antonucci, S, McCormack, S, Lynn, W, Bevan, M, Fox, J, Teague, A, Anderson, J, Mguni, S, Post, F, Campbell, L, Mazhude, C, Russell, H, Carrick, G, Ainsworth, J, Waters, A, Byrne, P, Johnson, M, Kuldanek, K, Mullaney, S, Lawlor, V, Melville, R, Sukthankar, A, Thorpe, S, Murphy, C, Wilkins, E, Ahmad, S, Green, P, Tayal, S, Ong, E, Meaden, J, Riddell, L, Loay, D, Peacock, K, Blackman, H, Harindra, V, Saeed, A M, Allen, S, Natarajan, U, Williams, O, Lacey, H, Care, C, Bowman, C, Herman, S, Devendra, S V, Wither, J, Bridgwood, A, Singh, G, Bushby, S, Kellock, D, Young, S, Rooney, G, Snart, B, Currie, J, Fitzgerald, M, Arumainayyagam, J, Chandramani, S, Rajamanoharan, S, Robinson, T, Taylor, B, Brewer, C, Mayr, Christoph, Schmidt, Wolfgang, Speidel, Andrea, Strohbach, Frank, Arastéh, Keikawus, Cordes, Christiane, Stündel, Manfred, Claus, Jörg, Baumgarten, Axel, Carganico, Andreas, Ingiliz, Patrick, Dupke, Stephan, Freiwald, Matthias, Rausch, Michael, Moll, Arend, Schleehauf, Dorothea, Hintsche, Bettina, Klausen, Gerd, Jessen, Heiko, Jessen, Arne, Köppe, Siegfried, Kreckel, Peter, Schranz, Dietmar, Fischer, Klaus, Schulbin, Hubert, Speer, Miriam, Glaunsinger, Tobias, Wicke, Thomas, Bieniek, Bernhard, Hillenbrand, Heribert, Schlote, Frank, Lauenroth-Mai, Elke, Schuler, Christoph, Schürmann, Dirk, Wesselmann, Hans, Brockmeyer, Norbert, Gehring, Peter, Schmalöer, Dirk, Hower, Martin, Spornraft-Ragaller, Petra, Häussinger, Dieter, Reuter, Stefan, Esser, Stefan, Markus, Rudolf, Kreft, Burkhard, Berzow, Dirk, Christl, Andreas, Meyer, Andreas, Plettenberg, Andreas, Stoehr, Albrecht, Graefe, Katrin, Lorenzen, Thore, Adam, Axel, Schewe, Knut, Weitner, Lutwin, Fenske, Stefan, Hansen, Stefan, Stellbrink, Hans-Jürgen, Wiemer, Dorothea, Hertling, Sandra, Schmidt, Reinhold, Arbter, Peter, Claus, Bernd, Galle, Peter, Jäger, Hans, Jä Gel-Guedes, Eva, Postel, Nils, Fröschl, Monika, Spinner, Christoph, Bogner, Johannes, Salzberger, Bernd, Schölmerich, Jürgen, Audebert, Franz, Marquardt, Ties, Schaffert, Andreas, Schnaitmann, Eiko, Trein, Andreas, Frietsch, Bernhard, Müller, Marcus, Ulmer, Albrecht, Detering-Hübner, Barbara, Kern, Peter, Schubert, Franz, Dehn, Günther, Schreiber, Maria, Güler, Cengiz, Schmidt, Daniel, Meixenberger, Karolin, Medical Microbiology & Infectious Diseases, Internal Medicine, Virology, Pediatrics, Medical Microbiology and Infection Prevention, AII - Infectious diseases, Global Health, Infectious diseases, APH - Aging & Later Life, Centre interdisciplinaire de recherche en biologie (CIRB), Labex MemoLife, École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Internal medicine, VU University medical center, Surgery, AMS - Rehabilitation & Development, APH - Quality of Care, Psychiatry, Pediatric surgery, Neurology, Public and occupational health, APH - Mental Health, Pathology, Cardiology, ACS - Heart failure & arrhythmias, Anesthesiology, IOO, Rehabilitation medicine, Obstetrics and gynaecology, General practice, Gastroenterology and hepatology, Pulmonary medicine, ACS - Pulmonary hypertension & thrombosis, Medical oncology laboratory, Hematology, Epidemiology and Data Science, Physiology, Microbes in Health and Disease (MHD), University of Oxford, Stichting HIV Monitoring [Amsterdam], Universiteit van Amsterdam (UvA), European Bioinformatics Institute [Hinxton] (EMBL-EBI), EMBL Heidelberg, Amsterdam UMC - Amsterdam University Medical Center, The Wellcome Trust Sanger Institute [Cambridge], Karolinska Institutet [Stockholm], Robert Koch Institute [Berlin] (RKI), Ecole Polytechnique Fédérale de Lausanne (EPFL), Johns Hopkins University (JHU), Universität Zürich [Zürich] = University of Zurich (UZH), Helsinki University Hospital [Helsinki, Finlande], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, National Institute of Allergy and Infectious Diseases [Bethesda] (NIAID-NIH), National Institutes of Health [Bethesda] (NIH), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, University College of London [London] (UCL), Kymab Ltd, Cambridge, England, Institut Pasteur [Paris] (IP), This study was funded by ERC Advanced Grant PBDR-339251 and a Li Ka Shing Foundation grant, both awarded to C.F. The ATHENA Cohort is managed by Stichting HIV Monitoring and supported by a grant from the Dutch Ministry of Health, Welfare and Sport through the Centre for Infectious Disease Control of the National Institute for Public Health and the Environment., We thank K. Fransen and G. Vanham for help with the Belgian data, O. Ratmann for help in identifying the Dutch clusters, K. Kusejko for testing for additional VB individuals in the SHCS, B. Foley for help with genome sharing, B. Dearlove and L. Thomson for help with software, and J. Herbeck and three other reviewers for helpful suggestions., Contributors and affiliations are listed in the supplementary materials., Department of Medicine, University of Helsinki, Infektiosairauksien yksikkö, HUS Inflammation Center, and Clinicum
Subjects: Adult, Male, HIV-1/genetics, Genotype, Anti-HIV Agents, Evolution, [SDV]Life Sciences [q-bio], lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], HIV Infections/drug therapy, selection, HIV Infections, Genome, Viral, heritability, epidemic, human-immunodeficiency-virus, Evolution, Molecular, SDG 3 - Good Health and Well-being, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Humans, Viral, Phylogeny, Netherlands, Multidisciplinary, Genome, model, Virulence, transmission, Molecular, setpoint viral load, reverse-transcriptase, dynamics, Viral Load, CD4 Lymphocyte Count, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], 3121 General medicine, internal medicine and other clinical medicine, Anti-HIV Agents/therapeutic use, Mutation, HIV-1, Female, progression
Abstract: Comment in Does HIV-1 virulence matter in the ART era? Lewitus E, Rolland M. Med (N Y). 2022 Apr 8;3(4):217-219. doi: 10.1016/j.medj.2022.03.003. PMID: 35590149; International audience; We discovered a highly virulent variant of subtype-B HIV-1 in the Netherlands. One hundred nine individuals with this variant had a 0.54 to 0.74 log 10 increase (i.e., a ~3.5-fold to 5.5-fold increase) in viral load compared with, and exhibited CD4 cell decline twice as fast as, 6604 individuals with other subtype-B strains. Without treatment, advanced HIV—CD4 cell counts below 350 cells per cubic millimeter, with long-term clinical consequences—is expected to be reached, on average, 9 months after diagnosis for individuals in their thirties with this variant. Age, sex, suspected mode of transmission, and place of birth for the aforementioned 109 individuals were typical for HIV-positive people in the Netherlands, which suggests that the increased virulence is attributable to the viral strain. Genetic sequence analysis suggests that this variant arose in the 1990s from de novo mutation, not recombination, with increased transmissibility and an unfamiliar molecular mechanism of virulence.
Published: 2022

12. EPV154/#117 HIV testing in cervical dysplasia, practitioners’ opinion

Author: van de Laar, R, primary, Jordans, C, additional, Rokx, C, additional, van Beekhuizen, H, additional, and van Doorn, HC, additional
Published: 2021
Full Text: View/download PDF

13. 206 HIV testing in cervical dysplasia, practitioners’ opinion

Author: Van de Laar, R, primary, Jordans, C, additional, Rokx, C, additional, Van Beekhuizen, HJ, additional, and Van Doorn, HC, additional
Published: 2021
Full Text: View/download PDF

14. Clinical outcomes of hospitalized COVID-19 patients by disease severity treated with remdesivir - NEAT ID 909REM Study

Author: Arber, N, Shah, P, Raffi, F, Assoumou, L, Rokx, C, De Castro, N, Bakhai, A, Viladomiu, AS, Mateu, L, Bermejo, CL, Estrada, V, Fabregas, AC, Sellier, PO, Duffy, A, Fletcher, C, Mozaffari, E, Haubrich, R, Hodgkins, P, and Pozniak, A
Published: 2021

15. A European review of HIV testing recommendations in national specialty guidelines for the management of HIV indicator conditions

Author: Jordans, C. C., Rae, C., Jacobsen, M. L., Akinosoglou, K., Arends, J., Dauby, N., Hachfeld, A., Malin, J. J., Matulionyte, R., Nozza, S., Pokrovskaya, A., Sandulescu, O., Thompson, M., Vassilenko, A., Torti, C., Giacomelli, A., Lapadula, G., Mazzitelli, M., Behrens, G., Spinner, C., Gruell, H., Neumann, Anja, Kostaki, E. G., Ankiersztejn-Bartczak, M., Skrzat-Klapaczynska, A., Matulyte, E., Lord, E., Sullivan, A., Rokx, C., and Grp, Guidelines Europe Review
Subjects: Medizin
Published: 2021

16. Use of the NEWS2 score in clinical outcomes of hospitalized COVID-19 patients by disease severity treated with remdesivir

Author: Shah, P, Viladomiu, AS, De Castro, N, Assoumou, L, Raffi, F, Arber, N, Rokx, C, Bakhai, A, Mateu, L, Bermejo, CL, Estrada, V, Fabregas, AC, Sellier, PO, Duffy, A, Fletcher, C, Mozaffari, E, Haubrich, R, Hodgkins, P, and Pozniak, A
Published: 2021

17. Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy

Author: Rokx, C, Verbon, A, and Rijnders, B JA
Published: 2014
Full Text: View/download PDF

18. Charles Boucher’s obituary-A visionary HIV scientist and educationalist

Author: Prins, H.A.B., primary and Rokx, C., additional
Published: 2021
Full Text: View/download PDF

19. Launching a multidisciplinary European collaboration towards a cure for HIV: The EU2Cure Consortium

Author: Rokx, C., primary, Prins, H.A.B., additional, Vandekerckhove, L., additional, Fidler, S.J., additional, Frater, J., additional, Bracchi, M., additional, Søgaard, O.S., additional, Tolstrop, M., additional, Rasmussen, T.A., additional, Salgado, M., additional, Blanco, J., additional, Martinez-Picado, J., additional, Clotet, B., additional, Tambussi, G., additional, Groenendijk, A., additional, Verbon, A., additional, and Boucher, C.A.B., additional
Published: 2021
Full Text: View/download PDF

20. The dolutegravir/valproic acid drug–drug interaction is primarily based on protein displacement

Author: Bollen, P D J, primary, Prins, H A B, additional, Colbers, A, additional, Velthoven-Graafland, K, additional, Rijnders, B J A, additional, de Vries-Sluijs, T E M S, additional, van Nood, E, additional, Nouwen, J, additional, Bax, H, additional, de Mendonca Melo, M, additional, Verbon, A, additional, Burger, D M, additional, and Rokx, C, additional
Published: 2021
Full Text: View/download PDF

21. HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study

Author: Smit, Colette, primary, Boyd, Anders, additional, Rijnders, Bart J A, additional, van de Laar, Thijs J W, additional, Leyten, Eliane M, additional, Bierman, Wouter F, additional, Brinkman, Kees, additional, Claassen, Mark A A, additional, den Hollander, Jan, additional, Boerekamps, Anne, additional, Newsum, Astrid M, additional, Schinkel, Janke, additional, Prins, Maria, additional, Arends, Joop E, additional, Op de Coul, Eline L M, additional, van der Valk, Marc, additional, Reiss, Peter, additional, van der Valk, M., additional, Geerlings, S.E., additional, Goorhuis, A., additional, Hovius, J.W., additional, Lempkes, B., additional, Nellen, F.J.B., additional, van der Poll, T., additional, Prins, J.M., additional, van Vugt, M., additional, Wiersinga, W.J., additional, Wit, F.W.M.N., additional, van Duinen, M., additional, van Eden, J., additional, Hazenberg, A., additional, van Hes, A.M.H., additional, Pijnappel, F.J.J., additional, Smalhout, S.Y., additional, Weijsenfeld, A.M., additional, Jurriaans, S., additional, Back, N.K.T., additional, Zaaijer, H.L., additional, Berkhout, B., additional, Cornelissen, M.T.E., additional, Schinkel, C.J., additional, Wolthers, K.C., additional, Peters, E.J.G., additional, van Agtmael, M.A., additional, Autar, R.S., additional, Bomers, M., additional, Sigaloff, K.C.E., additional, Heitmuller, M., additional, Laan, L.M., additional, Ang, C.W., additional, van Houdt, R., additional, Jonges, M., additional, van den Berge, M., additional, Stegeman, A., additional, Baas, S., additional, Hage de Looff, L., additional, Buiting, A., additional, Reuwer, A., additional, Veenemans, J., additional, Wintermans, B., additional, Pronk, M.J.H., additional, Ammerlaan, H.S.M., additional, van den Bersselaar, D.N.J., additional, de Munnik, E.S., additional, Deiman, B., additional, Jansz, A.R., additional, Scharnhorst, V., additional, Tjhie, J., additional, Wegdam, M.C.A., additional, van Eeden, A., additional, Nellen, J., additional, Brokking, W., additional, Elsenburg, L.J.M., additional, Nobel, H., additional, van Kasteren, M.E.E., additional, Berrevoets, M.A.H., additional, Brouwer, A.E., additional, Adams, A., additional, van Erve, R., additional, de Kruijf-van de Wiel, B.A.F.M., additional, Keelan-Phaf, S., additional, van de Ven, B., additional, Buiting, A.G.M., additional, Murck, J.L., additional, de Vries-Sluijs, T.E.M.S., additional, Bax, H.I., additional, van Gorp, E.C.M., additional, de Jong-Peltenburg, N.C., additional, de Mendonça Melo, M., additional, van Nood, E., additional, Nouwen, J.L., additional, Rijnders, B.J.A., additional, Rokx, C., additional, Schurink, C.A.M., additional, Slobbe, L., additional, Verbon, A., additional, Bassant, N., additional, van Beek, J.E.A., additional, Vriesde, M., additional, van Zonneveld, L.M., additional, de Groot, J., additional, Boucher, C.A.B., additional, Koopmans, M.P.G., additional, van Kampen, J.J.A., additional, Branger, J., additional, Douma, R.A., additional, Cents-Bosma, A.S., additional, Duijf-van de Ven, C.J.H.M., additional, Schippers, E.F., additional, van Nieuwkoop, C., additional, van IJperen, J.M., additional, Geilings, J., additional, van Burgel, N.D., additional, Leyten, E.M.S., additional, van der Hut, G., additional, Gelinck, L.B.S., additional, Mollema, F., additional, Davids-Veldhuis, S., additional, Tearno, C., additional, Wildenbeest, G.S., additional, Heikens, E., additional, Groeneveld, P.H.P., additional, Bouwhuis, J.W., additional, Lammers, A.J.J., additional, Kraan, S., additional, van Hulzen, A.G.W., additional, Kruiper, M.S.M., additional, van der Bliek, G.L., additional, Bor, P.C.J., additional, Debast, S.B., additional, Wagenvoort, G.H.J., additional, Kroon, F.P., additional, de Boer, M.G.J., additional, Jolink, H., additional, Lambregts, M.M.C., additional, Roukens, A.H.E., additional, Scheper, H., additional, Dorama, W., additional, van Holten, N., additional, Claas, E.C.J., additional, Wessels, E., additional, den Hollander, J.G., additional, Brouwer, C.J., additional, Smit, J.V., additional, Struik-Kalkman, D., additional, van Niekerk, T., additional, El Moussaoui, R., additional, Pogany, K., additional, Pontesilli, O., additional, Lowe, S.H., additional, Oude Lashof, A.M.L., additional, Posthouwer, D., additional, van Wolfswinkel, M.E., additional, Ackens, R.P., additional, Burgers, K., additional, Schippers, J., additional, Weijenberg-Maes, B., additional, van Loo, I.H.M., additional, Havenith, T.R.A., additional, van Vonderen, M.G.A., additional, Kampschreur, L.M., additional, Faber, S., additional, Steeman-Bouma, R., additional, Al Moujahid, A., additional, Kootstra, G.J., additional, Delsing, C.E., additional, van der Burg-van de Plas, M., additional, Scheiberlich, L., additional, Kortmann, W., additional, van Twillert, G., additional, Renckens, R., additional, Ruiter-Pronk, D., additional, van Truijen-Oud, F.A., additional, Cohen Stuart, J.W.T., additional, Jansen, E.R., additional, Hoogewerf, M., additional, Rozemeijer, W., additional, van der Reijden, W.A., additional, Sinnige, J.C., additional, Brinkman, K., additional, van den Berk, G.E.L., additional, Blok, W.L., additional, Lettinga, K.D., additional, de Regt, M., additional, Schouten, W.E.M., additional, Stalenhoef, J.E., additional, Veenstra, J., additional, Vrouenraets, S.M.E., additional, Blaauw, H., additional, Geerders, G.F., additional, Kleene, M.J., additional, Kok, M., additional, Knapen, M., additional, van der Meché, I.B., additional, Mulder-Seeleman, E., additional, Toonen, A.J.M., additional, Wijnands, S., additional, Wttewaal, E., additional, Kwa, D., additional, van Crevel, R., additional, Dofferhoff, A.S.M., additional, ter Hofstede, H.J.M., additional, Hoogerwerf, J., additional, Keuter, M., additional, Richel, O., additional, Albers, M., additional, Grintjes-Huisman, K.J.T., additional, de Haan, M., additional, Marneef, M., additional, Strik-Albers, R., additional, Rahamat-Langendoen, J., additional, Stelma, F.F., additional, Burger, D., additional, Gisolf, E.H., additional, Hassing, R.J., additional, Claassen, M., additional, ter Beest, G., additional, van Bentum, P.H.M., additional, Langebeek, N., additional, Tiemessen, R., additional, Swanink, C.M.A., additional, van Lelyveld, S.F.L., additional, Soetekouw, R., additional, van der Prijt, L.M.M., additional, van der Swaluw, J., additional, Bermon, N., additional, Jansen, R., additional, Herpers, B.L., additional, Veenendaal, D., additional, Verhagen, D.W.M., additional, Lauw, F.N., additional, van Broekhuizen, M.C., additional, van Wijk, M., additional, Bierman, W.F.W., additional, Bakker, M., additional, Kleinnijenhuis, J., additional, Kloeze, E., additional, Middel, A., additional, Postma, D.F., additional, Stienstra, Y., additional, Wouthuyzen-Bakker, M., additional, Boonstra, A., additional, de Groot-de Jonge, H., additional, van der Meulen, P.A., additional, de Weerd, D.A., additional, Niesters, H.G.M., additional, van Leer-Buter, C.C., additional, Knoester, M., additional, Hoepelman, A.I.M., additional, Arends, J.E., additional, Barth, R.E., additional, Bruns, A.H.W., additional, Ellerbroek, P.M., additional, Mudrikova, T., additional, Oosterheert, J.J., additional, Schadd, E.M., additional, van Welzen, B.J., additional, Aarsman, K., additional, Griffioen-van Santen, B.M.G., additional, de Kroon, I., additional, van Berkel, M., additional, van Rooijen, C.S.A.M., additional, Schuurman, R., additional, Verduyn-Lunel, F., additional, Wensing, A.M.J., additional, Reiss, P., additional, Zaheri, S., additional, Boyd, A.C., additional, Bezemer, D.O., additional, van Sighem, A.I., additional, Smit, C., additional, Hillebregt, M., additional, de Jong, A., additional, Woudstra, T., additional, Bergsma, D., additional, Meijering, R., additional, van de Sande, L., additional, Rutkens, T., additional, van der Vliet, S., additional, de Groot, L., additional, van den Akker, M., additional, Bakker, Y., additional, El Berkaoui, A., additional, Bezemer, M., additional, Brétin, N., additional, Djoechro, E., additional, Groters, M., additional, Kruijne, E., additional, Lelivelt, K.J., additional, Lodewijk, C., additional, Lucas, E., additional, Munjishvili, L., additional, Paling, F., additional, Peeck, B., additional, Ree, C., additional, Regtop, R., additional, Ruijs, Y., additional, Schoorl, M., additional, Schnörr, P., additional, Scheigrond, A., additional, Tuijn, E., additional, Veenenberg, L., additional, Visser, K.M., additional, and Witte, E.C., additional
Published: 2021
Full Text: View/download PDF

22. Is reaching 90-90-90 enough to end AIDS? Lessons from Amsterdam

Author: Bree, G.J. de, Sighem, A. van, Zuilhof, W., Bergen, J.E.A.M. van, Prins, M., Heidenrijk, M., Valk, M. van der, Brokx, P., Reiss, P., Deug, F., Davidovich, U., Geerlings, S.E., Hoornenborg, E., Oomen, A., Bruinderink, M.L.G., Schat, N., Achterbergh, R.C.A., Agtmael, M. van, Ananworanich, J., Beek, D. van de, Berk, G.E.L. van den, Bezemer, D., Bijnen, A. van, Blok, W.L., Bogers, S., Bomers, M., Boucher, C.A.B., Brokking, W., Burger, D., Brinkman, K., Brinkman, N., Bruin, M. de, Bruisten, S., Coyer, L., Crevel, R. van, Daans, C.G., Derckx, T., Dijkstra, M., Duijnhoven, Y.T. van, Eeden, A. van, Elsenburg, L., Elshout, M.A.M. van den, Ester, C., Ersan, E., Felipa, P.E.V., Geijtenbeek, T.B.H., Gool, J. van, Goorhuis, A., Groot, M., Hankins, C.A., Heijnen, A., Hillebregt, M.M.J., Hogewoning, A., Hommenga, M., Hovius, J.W., Janssen, Y., Jong, K. de, Jongen, V., Kootstra, N.A., Koup, R.A., Kroon, F.P., Laar, T.J.W. van de, Lauw, F., Leeuwen, M.M. van, Lettinga, K., Linde, I., Loomans, D.S.E., Mouhebati, T., Mulder, B.J., Mulder, J., Nellen, F.J., Nijsters, A., Nobel, H., Oostvogel, P., Coul, E.L.M. op de, Peters, E., Peters, I.S., Poll, T. van der, Ratmann, O., Rokx, C., Rooijen, M.S. van, Loeff, M.F.S. van der, Schoute, W.E.M., Sonder, G.J., Veenstra, J., Verbon, A., Vries, H.J. de, Vrouenraets, S., Vugt, M. van, Wiersinga, W.J., Wit, F.W., Zaheri, S., Zantkuijl, P., Zelm, M.C. van, Zakowicz, A., Zimmermann, H.M.L., HIV Transmission Elimination, Virology, and Internal Medicine
Subjects: 0301 basic medicine, medicine.medical_specialty, Anti-HIV Agents, Immunology, Human immunodeficiency virus (HIV), MEDLINE, Hiv testing, medicine.disease_cause, epidemic, 03 medical and health sciences, 0302 clinical medicine, Acquired immunodeficiency syndrome (AIDS), SDG 3 - Good Health and Well-being, Virology, Environmental health, Medicine, Humans, 030212 general & internal medicine, Amsterdam, Hiv transmission, Netherlands, Acquired Immunodeficiency Syndrome, Oncology (nursing), business.industry, Transmission (medicine), Public health, virus diseases, HIV, Hematology, Integrated approach, medicine.disease, 030104 developmental biology, Infectious Diseases, Oncology, business
Abstract: Purpose of review Although cities present opportunities for infectious pathogens such as HIV to spread, public health infrastructure within these cities also provides opportunities to design effective approaches to eliminate transmission of these pathogens. The HIV Transmission Elimination AMsterdam (H-TEAM) Initiative, a consortium of relevant stakeholders involved in HIV prevention and care, designed an integrated approach to curb the HIV epidemic in Amsterdam, including providing preexposure prophylaxis (PrEP), increasing awareness of acute HIV infection, offering same-day test and treat, and improving indicator disease-driven HIV testing. Recent findings In 2013, approximately 230 people in Amsterdam were newly diagnosed with HIV, largely belonging to one of two key affected populations, namely MSM and people with a migration background. Since the start of H-TEAM in 2014, a decrease in new diagnoses was observed (130 in 2017), with an increasing proportion of MSM who had been diagnosed with a recent infection. Summary The H-TEAM shows that a city-based concerted effort is feasible. However, major challenges remain, such as reducing the number of late HIV diagnoses, and identifying and providing appropriate services to a diminishing group of individuals who are likely the source of transmission.
Published: 2019

23. High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis

Author: Hoornenborg, Elske, primary, Coyer, Liza, additional, Boyd, Anders, additional, Achterbergh, Roel Christiaan Alfons, additional, Schim van der Loeff, Maarten Franciscus, additional, Bruisten, Sylvia, additional, de Vries, Henry John Christiaan, additional, Koopsen, Jelle, additional, van de Laar, Thijs J.W., additional, Prins, Maria, additional, van Bergen, J.E.A.M., additional, de Bree, G.J., additional, Brokx, P., additional, Deug, F., additional, Heidenrijk, M., additional, Prins, M., additional, Reiss, P., additional, van der Valk, M., additional, Davidovich, U., additional, Geerlings, S.E., additional, Hoornenborg, E., additional, Oomen, A., additional, Sighem, A. van, additional, Zuilhof, W., additional, Bruinderink, M.L. Groot, additional, Achterbergh, R.C.A., additional, van Agtmael, M., additional, Ananworanich, J., additional, Van de Beek, D., additional, van den Berk, G.E.L., additional, Bezemer, D., additional, van Bijnen, A., additional, Blok, W.L., additional, Bogers, S., additional, Bomers, M., additional, Boucher, C.A.B., additional, Brokking, W., additional, Burger, D., additional, Brinkman, K., additional, Brinkman, N., additional, de Bruin, M., additional, Bruisten, S., additional, Coyer, L., additional, van Crevel, R., additional, Daans, C.G., additional, Dellemann, L., additional, Dijkstra, M., additional, van Duijnhoven, Y.T., additional, van Eeden, A., additional, Elsenburg, L., additional, van den Elshout, M.A.M., additional, Ester, C., additional, Ersan, E., additional, Felipa, P.E.V., additional, Frissen, P.H.J., additional, Geijtenbeek, T.B.H., additional, Godfried, M.H., additional, van Gool, J., additional, Goorhuis, A., additional, Groot, M., additional, Hankins, C.A., additional, Heijnen, A., additional, Hillebregt, M.M.J., additional, Hogewoning, A., additional, Hommenga, M., additional, Hovius, J.W., additional, Janssen, Y., additional, de Jong, K., additional, Jongen, V., additional, Kootstra, N.A., additional, Koup, R.A., additional, Kroon, F.P., additional, van de Laar, T.J.W., additional, Lauw, F., additional, van Leeuwen, M.M., additional, Lettinga, K., additional, Linde, I., additional, Loomans, D.S.E., additional, van der Meer, J.T., additional, Mouhebati, T., additional, Mulder, B.J., additional, Mulder, J., additional, Nellen, F.J., additional, Nijsters, A., additional, Nobel, H., additional, Oostvogel, P., additional, Op de Coul, E.L.M., additional, Peters, E., additional, Peters, I.S., additional, van der Poll, T., additional, Ratmann, O., additional, Rokx, C., additional, van Rooijen, M.S., additional, Schim van der Loeff, M.F., additional, Schoute, W.E.M., additional, Sonder, G.J., additional, Veenstra, J., additional, Verbon, A., additional, Verdult, F., additional, de Vocht, J., additional, de Vries, H.J., additional, Vrouenraets, S., additional, van Vugt, M., additional, Wiersinga, W.J., additional, Wit, F.W., additional, Woittiez, L.R., additional, Zaheri, S., additional, Zantkuijl, P., additional, van Zelm, M.C., additional, Żakowicz, A., additional, and Zimmermann, H.M.L., additional
Published: 2020
Full Text: View/download PDF

24. Antiretroviral Monotherapy for HIV: Game Over or Future Perspectives?

Author: Rijnders, Bart J A, primary and Rokx, C, additional
Published: 2019
Full Text: View/download PDF

25. Hitting the right target: Diagnosing undiagnosed HIV patients in the Netherlands

Author: Prins, H A B, Rokx, C, and Internal Medicine
Subjects: SDG 3 - Good Health and Well-being
Published: 2017

26. Increased Virological Failure in Naive HIV-1-Infected Patients Taking Lamivudine Compared With Emtricitabine in Combination with Tenofovir and Efavirenz or Nevirapine in the Dutch Nationwide ATHENA cohort

Author: Rokx, C., Fibriani, A., Vijver, D.A. van de, Verbon, A., Schutten, M., Gras, L., Rijnders, B.J., Koopmans †, P.P., Keuter, M., Ven, A.J.A.M. van der, Hofstede, H.J.M. ter, Dofferhoff, A.S.M., Warris, A., Crevel, R. van, Internal Medicine, Virology, Med Microbiol, Infect Dis & Infect Prev, RS: CAPHRI School for Public Health and Primary Care, Graduate School, Amsterdam institute for Infection and Immunity, Infectious diseases, Paediatric Infectious Diseases / Rheumatology / Immunology, Global Health, General Internal Medicine, Amsterdam Public Health, Center of Experimental and Molecular Medicine, and Other departments
Subjects: Microbiology (medical), Adult, Male, medicine.medical_specialty, Nevirapine, Efavirenz, lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], HIV Infections, Emtricitabine, Cohort Studies, chemistry.chemical_compound, SDG 3 - Good Health and Well-being, immune system diseases, Internal medicine, Antiretroviral Therapy, Highly Active, medicine, Humans, Treatment Failure, Netherlands, business.industry, Incidence, Hazard ratio, Lamivudine, virus diseases, Odds ratio, Middle Aged, Viral Load, Virology, Infectious Diseases, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], chemistry, Anti-Retroviral Agents, Cohort, HIV-1, Female, business, Viral load, medicine.drug
Abstract: Contains fulltext : 153151.pdf (Publisher’s version ) (Closed access) BACKGROUND: Guidelines for treatment of human immunodeficiency virus type 1 (HIV-1) infection consider lamivudine and emtricitabine to be interchangeable components in first-line combination antiretroviral therapy (cART). The evidence for their clinical equivalence in cART is inconsistent. The primary aim of this study was to evaluate the virological responses to lamivudine and emtricitabine in recommended cART. METHODS: This was an observational study using data from the AIDS Therapy Evaluation in the Netherlands (ATHENA) nationwide HIV cohort. The virological responses to lamivudine and emtricitabine were compared by multivariable adjusted logistic regression and Cox proportional hazard models. Sensitivity analyses included propensity score-adjusted models. RESULTS: Therapy-naive HIV-1-infected patients without baseline resistance (N = 4740) initiated lamivudine or emtricitabine with efavirenz/tenofovir or nevirapine/tenofovir. The use of lamivudine was associated with more virological failure at week 48 compared to emtricitabine with efavirenz/tenofovir (10.8% vs 3.6%; adjusted odds ratio [AOR], 1.78; 95% confidence interval [CI], 1.11-2.84) and nevirapine/tenofovir (27% vs 11%; AOR, 2.09; 95% CI, 1.25-3.52) in on-treatment analysis. Propensity score-adjusted models and intent-to-treat sensitivity analyses gave comparable results. The adjusted hazard ratio of virological failure at week 240 using lamivudine instead of emtricitabine was 2.35 (95% CI, 1.61-3.42) with efavirenz and 2.01 (95% CI, 1.36-2.98) with nevirapine. The inclusion of lamivudine or emtricitabine in cART did not influence the time to virological suppression within 48 weeks or the probability of virological rebound after successful virological suppression. CONCLUSIONS: The use of emtricitabine instead of lamivudine as part of cART was associated with better virological responses. These findings are relevant for settings with extensive use of lamivudine and for settings where generic lamivudine will be available.
Published: 2015

27. Predictors of virological failure in HIV-1-infected patients switching to dolutegravir maintenance monotherapy

Author: Wijting, IEA, primary, Rutsaert, SL, additional, Rokx, C, additional, Burger, DM, additional, Verbon, A, additional, van Kampen, JJA, additional, Boucher, CAB, additional, Rijnders, BJA, additional, and Vandekerckhove, L, additional
Published: 2018
Full Text: View/download PDF

28. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

Author: Gregson, J, Tang, M, Ndembi, N, Hamers, Rl, Marconi, Vc, Brooks, K, Theys, K, Arruda, M, Garcia, F, Monge, S, Kanki, Pj, Kumarasamy, N, Kerschberger, B, Mor, O, Charpentier, C, Todesco, E, Rokx, C, Gras, L, Halvas, Ek, Sunpath, H, Carlo, Dd, Antinori, A, Andreoni, M, Latini, A, Mussini, C, Aghokeng, A, Sonnerborg, A, Neogi, U, Fessel, Wj, Agolory, S, Yang, C, Blanco, Jl, Juma, Jm, Smit, E, Schmidt, D, Watera, C, Asio, J, Kirungi, W, Tostevin, A, Clumeck, N, Goedhals, D, Bester, Pa, Sabin, C, Mukui, I, Santoro, M, Perno, Cf, Hunt, G, Morris, L, Pillay, D, Schulter, E, Reyes-Teran, G, Romero, K, Avila-Rios, S, Sirivichayakul, S, Ruxrungtham, K, Mekprasan, S, Dunn, D, Kaleebu, P, Raizes, E, Kantor, R, Gupta, Rk, Rhee, S, Shafer, Rw, de Wit, Tfr, Diero, L, Camacho, R, Gunthard, Hf, Hoffmann, Cj, Di Carlo, D, El-Hay, T, van Vuuren, C, de Oliveira, T, Murakami-Ogasawara, A, [Pillay, Deenan] UCL, Dept Infect, London WC1E 6BT, England, [Gupta, Ravindra K.] UCL, Dept Infect, London WC1E 6BT, England, [Tang, Michele] Stanford Univ, Dept Med, Stanford, CA 94305 USA, [Rhee, Soo-Yon] Stanford Univ, Dept Med, Stanford, CA 94305 USA, [Shafer, Robert W.] Stanford Univ, Dept Med, Stanford, CA 94305 USA, [Gregson, John] London Sch Hyg & Trop Med, Dept Stat, London, England, [Ndembi, Nicaise] Inst Human Virol Nigeria, Abuja, Federal Capital, Nigeria, [Hamers, Raph L.] Univ Amsterdam, Acad Med Ctr, Amsterdam Inst Global Hlth & Dev, Dept Global Hlth, NL-1012 WX Amsterdam, Netherlands, [de Wit, Tobias F. Rinke] Univ Amsterdam, Acad Med Ctr, Amsterdam Inst Global Hlth & Dev, Dept Global Hlth, NL-1012 WX Amsterdam, Netherlands, [Hamers, Raph L.] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1012 WX Amsterdam, Netherlands, [de Wit, Tobias F. Rinke] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1012 WX Amsterdam, Netherlands, [Marconi, Vincent C.] Emory Univ, Rollins Sch Publ Hlth, Dept Global Hlth, Atlanta, GA 30322 USA, [Marconi, Vincent C.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA, [Diero, Lameck] Moi Univ, Eldoret, Kenya, [Diero, Lameck] Acad Model Providing Access Healthcare, Eldoret, Kenya, [Brooks, Katherine] Brown Univ, Alpert Med Sch, Div Infect Dis, Providence, RI 02912 USA, [Theys, Kristof] KU Leuven Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, B-3000 Leuven, Belgium, [Camacho, Ricardo] KU Leuven Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, B-3000 Leuven, Belgium, [Kantor, Rami] KU Leuven Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, B-3000 Leuven, Belgium, [Arruda, Monica] Univ Fed Rio de Janeiro, Inst Biol, LVM, BR-21941 Rio De Janeiro, Brazil, [Garcia, Frederico] Complejo Hosp Univ Granada, Granada, Spain, Univ Alcala de Henares, E-28871 Alcala De Henares, Spain, [Monge, Susana] CIBERESP, Madrid, Spain, [Gunthard, Huldrych F.] Univ Zurich, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland, [Gunthard, Huldrych F.] Univ Zurich, Inst Med Virol, Zurich, Switzerland, [Hoffmann, Christopher J.] Johns Hopkins Univ, Baltimore, MD USA, [Hoffmann, Christopher J.] Aurum Inst, Johannesburg, South Africa, [Kanki, Phyllis J.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA, [Kumarasamy, Nagalingeshwaran] VHS, YRGCARE Med Ctr, Chennai, Tamil Nadu, India, [Kerschberger, Bernard] Med Sans Frontieres Operat Ctr Geneva, Mbabane, Eswatini, [Mor, Orna] Israel Minist Hlth, Publ Hlth Serv, Cent Virol Lab, Jerusalem, Israel, [Charpentier, Charlotte] Univ Paris Diderot, Sorbonne Paris Cite, IAME, UMR 1137, Paris, France, [Charpentier, Charlotte] INSERM, IAME, UMR 1137, Paris, France, [Charpentier, Charlotte] Hop Bichat Claude Bernard, AP HP, Virol Lab, F-75018 Paris, France, [Todesco, Eva] Hop La Pitie Salpetriere, Lab Virol, Paris, France, [Rokx, Casper] Erasmus Univ, Med Ctr, Dept Internal Med Infect Dis, Rotterdam, Netherlands, [Gras, Luuk] Stichting HIV Monitoring, Amsterdam, Netherlands, [Halvas, Elias K.] Univ Pittsburgh, Pittsburgh, PA USA, [Sunpath, Henry] Ethekwini Dist Hlth Off, Kwa Zulu, South Africa, [Di Carlo, Domenico] Univ Roma Tor Vergata, Dept Expt Med & Surg, Rome, Italy, [Santoro, Maria M.] Univ Roma Tor Vergata, Dept Expt Med & Surg, Rome, Italy, [Antinori, Antonio] INMI L Spallanzani, Infect Dis Unit, Rome, Italy, [Andreoni, Massimo] Univ Hosp Tor Vergata, Clin Infect Dis, Rome, Italy, [Latini, Alessandra] San Gallicano Dermatol Inst, HIV AIDS Unit, Rome, Italy, [Mussini, Cristina] Azienda Osped Univ Policlin, Clin Infect Dis, Modena, Italy, [Aghokeng, Avelin] Virol Lab CREMER IMPM, Yaounde, Cameroon, [Sonnerborg, Anders] Karolinska Inst, Div Clin Microbiol, Stockholm, Sweden, [Neogi, Ujjwal] Karolinska Inst, Div Clin Microbiol, Stockholm, Sweden, [Sonnerborg, Anders] Karolinska Inst, Infect Dis Unit, Stockholm, Sweden, [Neogi, Ujjwal] Karolinska Inst, Infect Dis Unit, Stockholm, Sweden, [Sonnerborg, Anders] Karolinska Univ Hosp, Stockholm, Sweden, [Neogi, Ujjwal] Karolinska Univ Hosp, Stockholm, Sweden, [Fessel, William J.] Kaiser Permanente Med Care Program Northern Calif, San Francisco, CA USA, [Agolory, Simon] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA, [Raizes, Elliot] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA, [Yang, Chunfu] Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA, [Blanco, Jose L.] Univ Barcelona, Inst Invest Biomed August Pi i Sunyer, Clin Univ, Barcelona, Spain, [Juma, James M.] Minist Hlth & Social Welf, Dar Es Salaam, Tanzania, [Smit, Erasmus] Publ Hlth England, Publ Hlth Lab, Birmingham, W Midlands, England, [Schmidt, Daniel] Robert Koch Inst, Dept Infect Dis Epidemiol HIV AIDS STI & Blood Bo, Berlin, Germany, [Watera, Christine] Uganda Res Unit AIDS, Entebbe, Uganda, [Asio, Juliet] Uganda Res Unit AIDS, Entebbe, Uganda, [Kaleebu, Pontiano] Uganda Res Unit AIDS, Entebbe, Uganda, [Tostevin, Anna] Minist Hlth, Kampala, Uganda, [Tostevin, Anna] UCL, MRC Clin Trials Unit, London, England, [Dunn, David] UCL, MRC Clin Trials Unit, London, England, [El-Hay, Tal] IBM Haifa Res Lab, Haifa, Israel, [Clumeck, Nathan] Univ Libre Bruxelles, St Pierre Univ Hosp, Brussels, Belgium, [Goedhals, Dominique] Univ Orange Free State, Dept Med Microbiol & Virol, Natl Hlth Lab Serv, Bloemfontein, South Africa, [van Vuuren, Cloete] Univ Orange Free State, Dept Med Microbiol & Virol, Natl Hlth Lab Serv, Bloemfontein, South Africa, [Sabin, Caroline] UCL, Infect & Populat Hlth, London, England, [Mukui, Irene] Minist Hlth, Natl AIDS & STI Control Programme, Nairobi, Kenya, [Perno, Carlo F.] INMI L Spallanzani, Antiretroviral Drugs Monitoring Unit, Rome, Italy, [Hunt, Gillian] Natl Inst Communicable Dis, Johannesburg, South Africa, [Morris, Lynn] Natl Inst Communicable Dis, Johannesburg, South Africa, [de Oliveira, Tulio] Wellcome Trust Africa Ctr Hlth & Populat Studies, Durban, South Africa, [Pillay, Deenan] Wellcome Trust Africa Ctr Hlth & Populat Studies, Durban, South Africa, [de Oliveira, Tulio] Univ KwaZulu Natal, Coll Hlth Sci, Durban, South Africa, [Schulter, Eugene] Univ Cologne, Inst Virol, D-50931 Cologne, Germany, [Murakami-Ogasawara, Akio] Natl Inst Resp Dis, Ctr Res Infect Dis, Mexico City, DF, Mexico, [Sirivichayakul, Sunee] Chulalongkorn Univ, Dept Med, Bangkok, Thailand, [Ruxrungtham, Kiat] Chulalongkorn Univ, Dept Med, Bangkok, Thailand, [Mekprasan, Suwanna] Chulalongkorn Univ, Dept Med, Bangkok, Thailand, [Kaleebu, Pontiano] MRC UVRI Uganda Res Unit AIDS, Entebbe, Uganda, Wellcome Trust, MRC, NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, and Medical Research Council
Subjects: Cyclopropanes, Anti-HIV Agents, K65r, Drug Resistance, Antiretroviral Therapy, HIV Infections, Global Health, Settore MED/07, Virological failure, Tenofovir disoproxil fumarate, Antiretroviral Therapy, Highly Active, Drug Resistance, Viral, Humans, Emtricitabine, Transmission, Highly Active, Viral, Tenofovir, Africa South of the Sahara, Benzoxazines, HIV-1, Lamivudine, Pre-Exposure Prophylaxis, Retrospective Studies, Reverse Transcriptase Inhibitors, Viral Load, Hiv-1-infected patients, virus diseases, Articles, Antiretroviral therapy, Naive patients, Alkynes, Efavirenz
Abstract: Summary Background Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent tenofovir disoproxil fumarate-containing regimens are increasingly used to treat and prevent HIV, although few data exist for frequency and risk factors of acquired drug resistance in regions hardest hit by the HIV pandemic. We aimed to do a global assessment of drug resistance after virological failure with first-line tenofovir-containing ART. Methods The TenoRes collaboration comprises adult HIV treatment cohorts and clinical trials of HIV drug resistance testing in Europe, Latin and North America, sub-Saharan Africa, and Asia. We extracted and harmonised data for patients undergoing genotypic resistance testing after virological failure with a first-line regimen containing tenofovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleotide reverse-transcriptase inhibitor (NNRTI; efavirenz or nevirapine). We used an individual participant-level meta-analysis and multiple logistic regression to identify covariates associated with drug resistance. Our primary outcome was tenofovir resistance, defined as presence of K65R/N or K70E/G/Q mutations in the reverse transcriptase (RT) gene. Findings We included 1926 patients from 36 countries with treatment failure between 1998 and 2015. Prevalence of tenofovir resistance was highest in sub-Saharan Africa (370/654 [57%]). Pre-ART CD4 cell count was the covariate most strongly associated with the development of tenofovir resistance (odds ratio [OR] 1·50, 95% CI 1·27–1·77 for CD4 cell count
Published: 2016

29. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

Author: Gregson, J, Tang, M, Ndembi, N, Hamers, R, Marconi, V, Brooks, K, Theys, K, Arruda, M, Garcia, F, Monge, S, Kanki, P, Kumarasamy, N, Kerschberger, B, Mor, O, Charpentier, C, Todesco, E, Rokx, C, Gras, L, Halvas, E, Sunpath, H, Carlo, D, Antinori, A, Andreoni, M, Latini, A, Mussini, C, Aghokeng, A, Sonnerborg, A, Neogi, U, Fessel, W, Agolory, S, Yang, C, Blanco, J, Juma, J, Smit, E, Schmidt, D, Watera, C, Asio, J, Kirungi, W, Tostevin, A, Clumeck, N, Goedhals, D, Bester, P, Sabin, C, Mukui, I, Santoro, M, Perno, C, Hunt, G, Morris, L, Camacho, R, Pillay, D, Schulter, E, Reyes-Terán, G, Romero, K, Avila-Rios, S, Sirivichayakul, S, Ruxrungtham, K, Mekprasan, S, Dunn, D, Kaleebu, P, Raizes, E, Kantor, R, Shafer, R, Gupta, R, Rhee, S, De Wit, T, Diero, L, Günthard, H, Hoffmann, C, and Di Carlo, D
Subjects: virus diseases
Abstract: Background Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent tenofovir disoproxil fumarate-containing regimens are increasingly used to treat and prevent HIV, although few data exist for frequency and risk factors of acquired drug resistance in regions hardest hit by the HIV pandemic. We aimed to do a global assessment of drug resistance after virological failure with first-line tenofovir-containing ART. Methods The TenoRes collaboration comprises adult HIV treatment cohorts and clinical trials of HIV drug resistance testing in Europe, Latin and North America, sub-Saharan Africa, and Asia. We extracted and harmonised data for patients undergoing genotypic resistance testing after virological failure with a first-line regimen containing tenofovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleotide reverse-transcriptase inhibitor (NNRTI; efavirenz or nevirapine). We used an individual participant-level meta-analysis and multiple logistic regression to identify covariates associated with drug resistance. Our primary outcome was tenofovir resistance, defined as presence of K65R/N or K70E/G/Q mutations in the reverse transcriptase (RT) gene. Findings We included 1926 patients from 36 countries with treatment failure between 1998 and 2015. Prevalence of tenofovir resistance was highest in sub-Saharan Africa (370/654 [57%]). Pre-ART CD4 cell count was the covariate most strongly associated with the development of tenofovir resistance (odds ratio [OR] 1·50, 95% CI 1·27–1·77 for CD4 cell count
Published: 2015

30. Predictors of virological failure in HIV‐1‐infected patients switching to dolutegravir maintenance monotherapy.

Author: Wijting, IEA, Rutsaert, SL, Rokx, C, Burger, DM, Verbon, A, Kampen, JJA, Boucher, CAB, Rijnders, BJA, and Vandekerckhove, L
Subjects: DIAGNOSIS of HIV infections, ANTIRETROVIRAL agents, BLOOD cells, COMBINATION drug therapy, DNA, GENERIC drug substitution, HIV infections, RNA, STATISTICS, T cells, VIROLOGY, RANDOMIZED controlled trials, TREATMENT effectiveness
Abstract: Objectives: The Dolutegravir Monotherapy for HIV (DOMONO; NCT02401828) study showed that maintenance monotherapy with dolutegravir (DTG) is associated with virological failure (VF) and leads to DTG resistance and as a result should not be used. However, data on clinical and virological factors associated with VF during DTG monotherapy are lacking. We identified factors associated with VF during DTG monotherapy. Methods: A randomized trial was carried out in which patients on combination antiretroviral therapy (cART) with an HIV‐1 RNA zenith < 100 000 copies/mL and a CD4 T‐cell nadir ≥ 200 cells/μL, who had never experienced VF, switched to DTG monotherapy. Clinical and virological factors were compared between patients with and without VF, using univariate analyses. Results: Eight of the 95 patients developed VF during DTG monotherapy. A total of 78 participants had reached week 48 when the study was discontinued. The median CD4 T‐cell nadir was lower in patients with VF than in patients without VF [260 (interquartile range (IQR) 223–320) versus 380 (IQR 290–520) cells/μL, respectively; P = 0.011]. Patients with VF had a longer time between HIV diagnosis and cART initiation than those without VF [median 49 (IQR 27–64) versus 15 (IQR 1–38) months, respectively; P = 0.015]. The median total peripheral blood mononuclear cell (PBMC) HIV DNA copy number was higher in patients with VF than in those without VF [417 (range 85–4151) versus 147 (range 16–4132) copies/106PBMCs, respectively; P = 0.022]. Conclusions: A lower CD4 nadir, a longer time between HIV diagnosis and cART initiation, and a higher HIV DNA copy number at the time of DTG monotherapy initiation were associated with VF. While there clearly is no future role for DTG monotherapy, ongoing and future studies on the efficacy of maintenance dual therapy (e.g. DTG lamivudine) may have to take these variables into account in their study design and analysis. [ABSTRACT FROM AUTHOR]
Published: 2019
Full Text: View/download PDF

31. 38 Small molecule inhibitors of BAF; a new family of compounds in HIV-1 latency reversal

Author: De Crignis, E., primary, Stoszko, M., additional, Rokx, C., additional, Khalid, M.M., additional, Lungu, C., additional, Palstra, R.-J., additional, Kan, T.-W., additional, Boucher, C., additional, Verbon, A., additional, Dykhuizen, E.C., additional, and Mahmoudi, T., additional
Published: 2016
Full Text: View/download PDF

32. Risk factors in an HIV-infected population for refraining from specialist care

Author: van Andel, E., primary, Been, S.K., additional, Rokx, C., additional, and van der Ende, M.E., additional
Published: 2016
Full Text: View/download PDF

33. Trombocytopenie tijdens de zwangerschap

Author: Rokx, C, Swart, RM, Houten, Antje, Leys, Duvekot, J.J., te Boekhorst, Peter, Internal Medicine, Hematology, and Obstetrics & Gynecology
Published: 2013

34. Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort

Author: Rokx, C., Gras, L., van de Vijver, D. A M C, Verbon, A., Rijnders, B. J A, Prins, J. M., Kuijpers, T. W., Scherpbier, H. J., van der Meer, J. T M, Wit, F. W M N, Godfried, M. H., Reiss, P., van der Poll, T., Nellen, F. J B, Lange, J. M A, Geerlings, S. E., van Vugt, M., Pajkrt, D., Bos, J. C., van der Valk, M, Wiersinga, W. J., Goorhuis, A., Hovius, J. W R, Lowe, S., Oude Lashof, A., Posthouwer, D., Pronk, M. J H, Ammerlaan, H. S M, van der Ende, M. E., de Vries-Sluijs, T. E M S, Schurink, C. A M, Nouwen, J. L., van Gorp, E. C M, van der Feltz, M., Driessen, G. J A, van Rossum, A. M C, Branger, J., Schippers, E. F., van Nieuwkoop, C., van Elzakker, E. P., Groeneveld, P. H P, Bouwhuis, J. W., Soetekouw, R., ten Kate, R. W., Kroon, F. P., van Dissel, J. T., Arend, S. M., de Boer, M. G J, Jolink, H., Vollaard, A. M., Bauer, M. P., den Hollander, J. G., Pogany, K., van Twillert, G., Kortmann, W., Cohen Stuart, J. W T, Diederen, B. M W, Leyten, E. M S, Gelinck, L. B S, Kootstra, G. J., Delsing, C. E., Brinkman, K., Blok, W. L., Frissen, P. H J, Schouten, W. E M, van den Berk, G. E L, van Kasteren, M. E E, Brouwer, A.E., Veenstra, J., Lettinga, K. D., Mulder, J. W., Vrouenraets, S. M E, Lauw, F. N., van Eeden, A., Verhagen, D. W M, Sprenger, H. G., Scholvinck, E. H., van Assen, S., Bierman, W. F W, Wilting, K. R., Stienstra, Y., Koopmans, P. P., Keuter, M., van der Ven, A. J A M, ter Hofstede, H. J M, Dofferhoff, A. S M, Warris, A., van Crevel, R., Hoepelman, A. I M, Mudrikova, T., Schneider, M. M E, Ellerbroek, P. M., Oosterheert, J. J., Arends, J. E., Wassenberg, M. W M, Barth, R. E., van Agtmael, M. A., Perenboom, R. M., Claessen, F. A P, Bomers, M., Peters, E.J.G., Geelen, S. P M, Wolfs, T. F W, Bont, L. J., Richter, C., van der Berg, J. P., Gisolf, E. H., van den Berge, M., Stegeman, A., van Vonderen, M. G A, van Houte, D. P F, Weijer, S., el Moussaoui, R., Winkel, C., Muskiet, F., Durand, A., Voigt, R., Medische Microbiologie, MUMC+: DA MMI Staf (9), MUMC+: MA Alg Interne Geneeskunde (9), RS: FHML non-thematic output, AII - Infectious diseases, Internal medicine, ICaR - Circulation and metabolism, Internal Medicine, Virology, Medical Microbiology & Infectious Diseases, Amsterdam institute for Infection and Immunity, Infectious diseases, Paediatric Infectious Diseases / Rheumatology / Immunology, Global Health, General Internal Medicine, Amsterdam Public Health, Center of Experimental and Molecular Medicine, Graduate School, and Other departments
Subjects: Male, 0301 basic medicine, HIV-1 INFECTION, boosted protease inhibitors, HIV Infections, Pharmacology, Cohort Studies, 0302 clinical medicine, REVERSE-TRANSCRIPTASE, RESISTANCE PROFILES, Antiretroviral Therapy, Highly Active, ABACAVIR-LAMIVUDINE, Pharmacology (medical), Treatment Failure, 030212 general & internal medicine, Netherlands, MULTICENTER TRIAL, Health Policy, Hazard ratio, CONTAINING REGIMENS, Lamivudine, virus diseases, Lopinavir, Middle Aged, Viral Load, ANTIRETROVIRAL-NAIVE, Infectious Diseases, Cohort, INITIAL TREATMENT, Female, lamivudine, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Anti-HIV Agents, 030106 microbiology, antiretroviral therapy, Observational Study, Emtricitabine, Young Adult, 03 medical and health sciences, ONCE-DAILY DOLUTEGRAVIR, SDG 3 - Good Health and Well-being, Internal medicine, medicine, Journal Article, Humans, Comparative Study, Darunavir, emtricitabine, business.industry, Odds ratio, Atazanavir, SUPPRESSED PATIENTS, HIV-1, business
Abstract: ObjectivesLamivudine (3TC) and emtricitabine (FTC) are considered interchangeable in recommended tenofovir disoproxil-fumarate (TDF)-containing combination antiretroviral therapies (cARTs). This statement of equivalence has not been systematically studied. We compared the treatment responses to 3TC and FTC combined with TDF in boosted protease inhibitor (PI)-based cART for HIV-1-infected patients.MethodsAn observational study in the AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort was carried out between 2002 and 2013. Virological failure rates, time to HIV RNA suppression ResultsA total of 1582 ART-naive HIV-1-infected patients initiated 3TC or FTC with TDF and ritonavir-boosted darunavir (29.6%), atazanavir (41.5%), lopinavir (27.1%) or another PI (1.8%). Week 48 virological failure rates on 3TC and FTC were comparable (8.9% and 5.6%, respectively; P = 0.208). The multivariable adjusted odds ratio of virological failure when using 3TC instead of FTC with TDF in PI-based cART was 0.75 [95% confidence interval (CI) 0.32-1.79; P = 0.51]. Propensity score-adjusted models showed comparable results. The adjusted hazard ratio (HR) for treatment failure of 3TC compared with FTC was 1.15 (95% CI 0.58-2.27) within 240 weeks after cART initiation. The time to two consecutive HIV RNA measurements ConclusionsThe virological responses were not significantly different in treatment-naive HIV-1-infected patients starting either 3TC/TDF or FTC/TDF and a ritonavir-boosted PI.
Published: 2016

35. Evidence Gathered From Randomized Clinical Trials and Observational Studies on the Equivalence of Emtricitabine and Lamivudine

Author: Rokx, C., primary and Rijnders, B. J. A., additional
Published: 2015
Full Text: View/download PDF

36. Goed bestuur volgens de Wereldbank: inhoud en betekenis van een spraakmakend concept

Author: Korsten, A.F.A., Rokx, C., Dam, R., Beusmans, B., Foundations and methods of Law, and RS: FdR niet-geprogrammeerd
Published: 2005

37. Peginterferon Alfa-2a for AIDS-Associated Kaposi Sarcoma: Experience With 10 Patients

Author: Rokx, C., primary, van der Ende, M. E., additional, Verbon, A., additional, and Rijnders, B. J. A., additional
Published: 2013
Full Text: View/download PDF

38. Governance and malnutrition: exploring the contribution of 'good governance' to malnutrition reduction in developing countries

Author: Rokx, C. and Rokx, C.
Published: 2006

39. Governance and malnutrition: exploring the contribution of ''good governance'' to malnutrition reduction in developing countries

Author: Rokx, C., primary
Full Text: View/download PDF

40. Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain

Author: Rokx C, Dd, Richman, Müller-Trutwin M, Silvestri G, Lunzen J, Khoo S, Lichterfeld M, Altfeld M, CARLO FEDERICO PERNO, Pw, Hunt, Mallon P, Jk, Rockstroh, Al, Pozniak, and Ca, Boucher

41. A European review of HIV testing recommendations in national specialty guidelines for the management of HIV indicator conditions

Author: Jordans, C. C., Rae, C., Jacobsen, M. L., Akinosoglou, K., Arends, J., Dauby, N., Hachfeld, A., Malin, J. J., Matulionyte, R., Nozza, S., Pokrovskaya, A., Sandulescu, O., Thompson, M., Vassilenko, A., Torti, C., Andrea Giacomelli, Lapadula, G., Mazzitelli, M., Behrens, G., Spinner, C., Gruell, H., Neumann, A., Kostaki, E. -G, Ankiersztejn-Bartczak, M., Skrzat-Klapaczynska, A., Matulyte, E., Lord, E., Sullivan, A., and Rokx, C.

42. Treatment of multicentric Castleman’s disease in HIV-1 infected and uninfected patients: a systematic review

Author: Rokx C, Bart Rijnders, and Ja, Laar
Subjects: Adult, Male, Interleukin-6, Castleman Disease, HIV Infections, Middle Aged, Receptors, Interleukin-6, Survival Rate, Antibodies, Monoclonal, Murine-Derived, Treatment Outcome, HIV-1, Humans, Female, Rituximab, Aged
Abstract: Multicentric Castleman's disease (MCD) is frequently associated with human-herpesvirus (HHV)-8, especially in human immunodeficiency virus (HIV)-1 co-infections. The optimal treatment is unclear. This systematic review provides an overview of available evidence on chemotherapeutic and monoclonal antibody therapies directed against CD20, interleukin (IL)6 or IL6 receptor.A systematic literature search of Embase, Medline, Web-of-Science, Scopus, PubMed publisher, Cochrane and Google Scholar was conducted for trials and cohort studies on MCD therapy. Baseline characteristics and reported endpoints were summarised and treatment efficacy was assessed by overall mortality rates.1817 studies were identified providing five trials and 14 cohort studies on 666 patients, including one randomised placebo-controlled trial. Ten studies reported on 450 HIV-1 positive patients. Most HIV-1 positive (99.7%), and 24.4% of HIV-1 negative patients were HHV-8 infected. Study populations and methods varied considerably. The use of rituximab was associated with better treatment responses and survival compared with chemotherapy without rituximab in HHV- associated, predominantly HIV-1 infected, MCD patients. Anti-IL6(receptor) antibodies might be promising second-line or salvage agents, at least in HIV-1 and HHV-8 negative patients. Kaposi sarcoma (re)activation with rituximab and MCD progression to aggressive lymphoma, or haemophagocytic lymphohistiocytosis were important complications.Optimal MCD treatment for HIV-1 and÷or HHV-8 positive or negative patients remains unclear. The available evidence is of low quality due to study designs, treatment allocation bias, and publication bias. MCD patients remain at risk for developing lymphomas or haemophagocytic lymphohistiocytosis. Rituximab may have survival benefits for HHV-8 associated MCD, but it is related to Kaposi sarcoma exacerbations.

43. Somatic complaints and social competence predict success in childhood overweight treatment.

Author: de Niet J, Timman R, Rokx C, Jongejan M, Passchier J, and van Den Akker E
Published: 2011
Full Text: View/download PDF

44. National medical specialty guidelines of HIV indicator conditions in Europe lack adequate HIV testing recommendations: a systematic guideline review

Author: Jordans, Carlijn C.E., Vasylyev, Marta, Rae, Caroline, Jakobsen, Marie Louise, Vassilenko, Anna, Dauby, Nicolas, Grevsen, Anne Louise, Jakobsen, Stine Finne, Raahauge, Anne, Champenois, Karen, Papot, Emmanuelle, Malin, Jakob J., Boender, T. Sonia, Behrens, Georg M.N., Gruell, Henning, Neumann, Anja, Spinner, Christoph D., Valbert, Frederik, Akinosoglou, Karolina, Kostaki, Evangelia G., Nozza, Silvia, Giacomelli, Andrea, Lapadula, Giuseppe, Mazzitelli, Maria, Torti, Carlo, Matulionyte, Raimonda, Matulyte, Elzbieta, Van Welzen, Berend J., Hensley, Kathryn S., Thompson, Magdalena, Ankiersztejn-Bartczak, Magdalena, Skrzat-Klapaczyńska, Agata, Sǎndulescu, Oana, Streinu-Cercel, Adrian, Streinu-Cercel, Anca, Miron, Viktor Daniel, Pokrovskaya, Anastasia, Hachfeld, Anna, Dorokhina, Antonina, Sukach, Maryna, Lord, Emily, Sullivan, Ann K., Rokx, Casper, Medical Microbiology & Infectious Diseases, Jordans, C, Vasylyev, M, Rae, C, Jakobsen, M, Vassilenko, A, Dauby, N, Grevsen, A, Jakobsen, S, Raahauge, A, Champenois, K, Papot, E, Malin, J, Boender, T, Behrens, G, Gruell, H, Neumann, A, Spinner, C, Valbert, F, Akinosoglou, K, Kostaki, E, Nozza, S, Giacomelli, A, Lapadula, G, Mazzitelli, M, Torti, C, Matulionyte, R, Matulyte, E, Van Welzen, B, Hensley, K, Thompson, M, Ankiersztejn-Bartczak, M, Skrzat-Klapaczyńska, A, Săndulescu, O, Streinu-Cercel, A, Miron, V, Pokrovskaya, A, Hachfeld, A, Dorokhina, A, Sukach, M, Lord, E, Sullivan, A, and Rokx, C
Subjects: Europe, SDG 3 - Good Health and Well-being, Epidemiology, HIV, indicator conditions, AIDS-defining condition, Virology, Public Health, Environmental and Occupational Health, Medizin, guidelines, Wirtschaftswissenschaften, 610 Medizin und Gesundheit
Abstract: Background Adequate identification and testing of people at risk for HIV is fundamental for the HIV care continuum. A key strategy to improve timely testing is HIV indicator condition (IC) guided testing. Aim To evaluate the uptake of HIV testing recommendations in HIV IC-specific guidelines in European countries. Methods Between 2019 and 2021, European HIV experts reviewed guideline databases to identify all national guidelines of 62 HIV ICs. The proportion of HIV IC guidelines recommending HIV testing was reported, stratified by subgroup (HIV IC, country, eastern/western Europe, achievement of 90–90–90 goals and medical specialty). Results Of 30 invited European countries, 15 participated. A total of 791 HIV IC guidelines were identified: median 47 (IQR: 38–68) per country. Association with HIV was reported in 69% (545/791) of the guidelines, and 46% (366/791) recommended HIV testing, while 42% (101/242) of the AIDS-defining conditions recommended HIV testing. HIV testing recommendations were observed more frequently in guidelines in eastern (53%) than western (42%) European countries and in countries yet to achieve the 90–90–90 goals (52%) compared to those that had (38%). The medical specialties internal medicine, neurology/neurosurgery, ophthalmology, pulmonology and gynaecology/obstetrics had an HIV testing recommendation uptake below the 46% average. None of the 62 HIV ICs, countries or medical specialties had 100% accurate testing recommendation coverage in all their available HIV IC guidelines. Conclusion Fewer than half the HIV IC guidelines recommended HIV testing. This signals an insufficient adoption of this recommendation in non-HIV specialty guidelines across Europe.
Published: 2022

45. Development of C-TILDA: A modified TILDA method for reservoir quantification in long term treated patients infected with subtype C HIV-1

Author: Vanessa D'Urbano, Tokameh Mahmoudi, Isabella Bon, Maria Carla Re, Charles A. Boucher, Annelies Verbon, Jeroen J. A. van Kampen, Casper Rokx, Elisa De Crignis, Alessia Bertoldi, Giorgio Gallinella, Rob A. Gruters, Leonardo Calza, Internal Medicine, Medical Microbiology & Infectious Diseases, Virology, Biochemistry, Bertoldi A., D'Urbano V., Bon I., Verbon A., Rokx C., Boucher C., van Kampen J.J.A., Gruters R.A., Gallinella G., Calza L., Mahmoudi T., De Crignis E., and Re M.C.
Subjects: 0301 basic medicine, CD4-Positive T-Lymphocytes, Serial dilution, Sustained Virologic Response, 030106 microbiology, Human immunodeficiency virus (HIV), CD4-CD8 Ratio, HIV Infections, Biology, medicine.disease_cause, Antiviral Agents, Sensitivity and Specificity, Virus, HIV Testing, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Virology, HIV subtype C, medicine, Humans, Cell stimulation, Gene, Messenger RNA, Hiv epidemiology, HIV, Viral Load, Virus Latency, 030104 developmental biology, Reservoir quantification, DNA, Viral, HIV-1, TILDA, CD8
Abstract: A better characterization of the HIV reservoir is pivotal for the development of effective eradication strategies. Accurate quantification of the latent reservoir remains challenging. Starting from a regular blood draw, the Tat/Rev induced limiting dilution assay (TILDA) combines serial dilution of CD4+ T cells with a PCR-based detection of HIV-1 spliced mRNA produced upon cell stimulation. Here we adapted the original protocol for HIV-1 subtype B to detect tat/rev mRNAs transcribed from reactivated latently infected cells in long term suppressed patients infected with HIV-1 subtype C. Given the heterogeneity of global HIV epidemiology, it is pivotal to develop assays with optimal performances also in patients infected with non-B subtypes. We observed that, in these patients infected with subtype C virus, the HIV reservoir quantified by TILDA correlates with both the time of virological suppression and CD4/CD8 ratio.
Published: 2019

46. The risk of non-AIDS defining events is lower in ART-naive HIV controllers than in normal progressors on suppressive ART.

Author: Groenendijk AL, Miranda Afonso P, Wit F, Blaauw MJT, van Eekeren LE, Otten T, Vos WAJW, Vadaq N, Dos Santos JC, van Lunzen J, van der Ven A, Rokx C, and Verbon A
Abstract: Background: We aimed to compare the non-AIDS events (nADE) risk between normal progressors using ART (NP-ART) and people with HIV (PWH) that naturally control HIV infection (HIV controllers), as well as the outcomes after ART in HIV controllers on nADE., Methods: The primary endpoint was major nADE defined as the composite of cardiovascular disease, non-AIDS malignancy or all-cause mortality, whichever came first.. The role of ART in HIV controllers was assessed as a time-varying covariate., Results: We included 1007 ART-naive HIV controllers (of which 60 elite controllers), 1510 Early-ART (<6 months after negative HIV test) and 15437 NP-ART (reference group), contributing 3813, 11,060 and 160,050 years of follow-up, respectively. HIV controllers had lower risk of the primary endpoint (HR 0.55, 95%CI 0.38-0.81, P = 0.0023), all-cause mortality (Adjusted Hazard ratio [aHR]: 0.45, 95% confidence interval [CI] 0.25-0.79, P = 0.0054), cardiovascular disease (aHR 0.47, 95%CI 0.22-0.99, P = 0.046) , but not non-AIDS malignancy (aHR 0.74, 95%CI 0.41-1.35, P = 0.33) than NP-ART. Among HIV controllers, each log10 lower baseline viral load further decreased the risk of nADE (aHR 0.54, 95% CI 0.29-0.99, P = 0.045). ART in HIV controllers did not reduce the risk of any nADE (aHR 1.22, 95% CI 0.66-2.29, P = 0.53)., Conclusions: We found a lower risk of nADE in HIV controllers than NP-ART, especially in those with low plasma viral loads. Initiation of ART did not alter the nADE risk in HIV controllers. Our findings help clinicians to decide on prescribing ART in HIV controllers., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
Published: 2024
Full Text: View/download PDF

47. Immunogenicity of a bivalent BA.1 COVID-19 booster vaccine in people with HIV in the Netherlands.

Author: Jongkees MJ, Tan NH, Geers D, de Vries RD, GeurtsvanKessel CH, Hensley KS, Sablerolles RSG, Bogers S, Gommers L, Blakaj B, Miranda Afonso P, Hansen BE, Rijnders BJA, Brinkman K, van der Kuy PHM, Roukens AHE, and Rokx C
Subjects: Humans, Male, Middle Aged, Female, Prospective Studies, Netherlands, Adult, 2019-nCoV Vaccine mRNA-1273 immunology, 2019-nCoV Vaccine mRNA-1273 administration & dosage, Cytokines immunology, Aged, Immunization, Secondary, HIV Infections immunology, COVID-19 prevention & control, COVID-19 immunology, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, Immunogenicity, Vaccine, Antibodies, Viral blood, Antibodies, Viral immunology, BNT162 Vaccine immunology, BNT162 Vaccine administration & dosage, SARS-CoV-2 immunology
Abstract: Objective: We evaluated the immunogenicity of a bivalent BA.1 COVID-19 booster vaccine in people with HIV (PWH)., Design: Prospective observational cohort study., Methods: PWH aged ≥45 years received Wuhan-BA.1 mRNA-1273.214 and those <45 years Wuhan-BA.1 BNT162b2. Participants were propensity score-matched 1 : 2 to people without HIV (non-PWH) by age, primary vaccine platform (mRNA-based or vector-based), number of prior COVID-19 boosters and SARS-CoV-2 infections, and spike (S1)-specific antibodies on the day of booster administration. The primary endpoint was the geometric mean ratio (GMR) of ancestral S1-specific antibodies from day 0 to 28 in PWH compared to non-PWH. Secondary endpoints included humoral responses, T-cell responses and cytokine responses up to 180 days post-vaccination., Results: Forty PWH received mRNA-1273.214 ( N = 35) or BNT162b2 ( N = 5) following mRNA-based ( N = 29) or vector-based ( N = 11) primary vaccination. PWH were predominantly male (87% vs. 26% of non-PWH) and median 57 years [interquartile range (IQR) 53-59]. Their median CD4 + T-cell count was 775 (IQR 511-965) and the plasma HIV-RNA load was <50 copies/ml in 39/40. The GMR of S1-specific antibodies by 28 days post-vaccination was comparable between PWH [4.48, 95% confidence interval (CI) 3.24-6.19] and non-PWH (4.07, 95% CI 3.42-4.83). S1-specific antibody responses were comparable between PWH and non-PWH up to 180 days, and T-cell responses up to 90 days post-vaccination. Interferon-γ, interleukin (IL)-2, and IL-4 cytokine concentrations increased 28 days post-vaccination in PWH., Conclusion: A bivalent BA.1 booster vaccine was immunogenic in well treated PWH, eliciting comparable humoral responses to non-PWH. However, T-cell responses waned faster after 90 days in PWH compared to non-PWH., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
Published: 2024
Full Text: View/download PDF

48. COVID-19 epidemiology and performance of the WHO clinical algorithm to diagnose COVID-19 in people with HIV from Ukraine.

Author: Vasylyev M, Buhiichyk V, Buhiichyck N, Groenendijk A, Ben I, Ostapiuk L, Sluzhynska M, Bierman WFW, van Kampen JJA, Wit FWNM, Reiss P, Rijnders BJA, Sluzhynska O, and Rokx C
Subjects: Humans, Ukraine epidemiology, Female, Male, Adult, Cross-Sectional Studies, Middle Aged, Prevalence, World Health Organization, Quality of Life, COVID-19 epidemiology, COVID-19 diagnosis, HIV Infections epidemiology, HIV Infections diagnosis, HIV Infections complications, SARS-CoV-2, Algorithms
Abstract: Background: The two main objectives were to evaluate the COVID-19 point prevalence and the test performance of the WHO case definition to diagnose COVID-19 clinically in people with HIV in West Ukraine., Methods: Multicenter cross-sectional study in Lviv, Ukraine, from October 2020-November 2021. COVID-19 unvaccinated people with HIV were included regardless of COVID-19 symptoms at routine clinical visits and had standardized medical, quality of life (EQ(5D)) and SARS-CoV-2 serology assessments. Reported symptoms indicating potential COVID-19 events at inclusion or between March 2020 and inclusion were classified by the WHO case definition as suspected, probable or confirmed. A clinical COVID-19 case was defined as being SARS-CoV-2 seropositive with at least a suspected COVID-19 according to the WHO case definition. The primary endpoints were the clinical COVID-19 prevalence and the test characteristics of the WHO case definition with SARS-CoV-2 serology as reference. (Clinicaltrials.gov:NCT04711954)., Results: The 971 included people with HIV were median 40 years, 38.8% women, 44.8% had prior AIDS, and 55.6% had comorbidities. SARS-CoV-2 seroprevalence was 40.1% (95%CI:37.0-43.1) and 20.5% (95%CI:18.0-23.1) had clinical COVID-19 median 4 months (IQR:2-7) before inclusion. Clinical COVID-19 occurred less frequently in people with HIV with tuberculosis history, injecting drug use, CD4+ T-cells <200/mL and unemployment. The quality of life was not impacted after COVID-19. An at least probable COVID-19 classification by the WHO case definition had 44.1% sensitivity (95%CI:38.7-49.7), 85.2% specificity (95%CI:81.5-88.4), 66.6% positive predictive value (95%CI:59.8-73.0) and 69.5% negative predictive value (95%CI:65.5-73.3) to diagnose COVID-19., Conclusions: COVID-19 unvaccinated people with HIV from Ukraine had a significant COVID-19 rate and using the WHO case definition had insufficient diagnostic accuracy to diagnose these cases. The lower burden in vulnerable people with HIV was unexpected but might reflect a shielding effect., Competing Interests: Declaration of conflicting interestThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Unrestricted grant from ISS program by ViiV Healthcare (grant nr. 214,684) and the Erasmus MC Foundation aware.hiv Ukraine program (https://www.awarehiv.com/ukraine). The funder had no role in the design of the study, data collection, analysis, writing or the decision to submit for publication. The authors declare no other conflict of interest related to this submission. Results from a planned interim analysis at 500 participants have been presented at EACS conference London, 2021.
Published: 2024
Full Text: View/download PDF

49. Author Correction: Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients.

Author: Millat-Martinez P, Gharbharan A, Alemany A, Rokx C, Geurtsvankessel C, Papageorgiou G, van Geloven N, Jordans C, Groeneveld G, Swaneveld F, van der Schoot E, Corbacho-Monné M, Ouchi D, Piccolo Ferreira F, Malchair P, Videla S, García García V, Ruiz-Comellas A, Ramírez-Morros A, Rodriguez Codina J, Amado Simon R, Grifols JR, Blanco J, Blanco I, Ara J, Bassat Q, Clotet B, Baro B, Troxel A, Zwaginga JJ, Mitjà O, and Rijnders BJA
Published: 2024
Full Text: View/download PDF

50. Perceptions of Rapid Antiretroviral Therapy Initiation Among Participants of The Netherlands Cohort Study on Acute HIV Infection.

Author: van Paassen P, Dijkstra M, Peay HL, Rokx C, Verbon A, Reiss P, Prins JM, Henderson GE, Rennie S, Nieuwkerk PT, and de Bree GJ
Subjects: Humans, Male, Netherlands epidemiology, Female, Adult, Cohort Studies, Middle Aged, Qualitative Research, Anti-Retroviral Agents therapeutic use, Anti-HIV Agents therapeutic use, Interviews as Topic, Health Knowledge, Attitudes, Practice, Patient Acceptance of Health Care psychology, HIV Infections drug therapy, HIV Infections psychology
Abstract: Starting antiretroviral therapy (ART) same-day, or as soon as possible after HIV diagnosis is advised in guidelines worldwide. Especially during acute HIV infection (AHI), rapid ART start may be more urgent because of a higher risk of transmission or symptoms of acute retroviral syndrome. During this phase, rapid ART start may have additional benefits for viral reservoir size and host immunity. We explored perceptions of rapid ART start among participants of The Netherlands Cohort Study on Acute HIV infection (NOVA study), who started ART rapidly after diagnosis of AHI. We conducted 20 in-depth qualitative interviews with NOVA study participants between October and December 2018. Data were analyzed thematically, using inductive and iterative coding techniques. Roughly half of the participants stated they felt well-informed about the importance of (rapid) ART. Starting ART rapidly was perceived positively by almost all participants, mostly because of the expected benefits on their health, and to prevent HIV transmission. Rapid ART start was seen as a way to cope with the diagnosis. However, a more negative perception was that rapid ART start confronted participants with their diagnosis, when they were still adjusting to a new situation. Our results show that among people diagnosed during AHI, rapid ART is well-accepted. These results should be encouraging to HIV care providers who encounter people with AHI in their clinical practice and to researchers who carry out cure-related studies, in which early ART is often included. The Clinical Trial Registration number is NCT05728996.
Published: 2024
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

158 results on '"Rokx, C."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources